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PROFESSOR JÁNOS SZILÁRD 
Opening speech 
Honoured Guests! 
On this remarkable day let me greet Károly Németh the President of the 
Presidium of the Hungarian People's Republic, the members of the Szent-Györgyi 
family here present, the representatives of the Diplomatic corps, the Ministry of 
Health and Cultural Affairs, the Hungarian Academy of Sciences, the representat-
ives of the Communist Party, and state and social organizations of Szeged and 
Csongrád County. I also wish to welcome colleagues from Hungarian and foreign 
Universities, professors, honorary doctors, lecturers and students of our University. 
Upon the request of the Council of the Szeged University of Medical Sciences, 
the Presidium of the Hungarian People's Republic has approved the renaming our 
University after Albert Szent-Györgyi who was the Head of the Department of 
Medical Chemistry between 1928 and 1945, as well as dean and rector of the 
University. I am convinced that any explanation is unnecessary why the Szeged 
University of Medical Sciences wishes to bear the name of Albert Szent-Györgyi. 
This decision, which was formulated even in Szent-Györgyi's lifetime, and 
cherished since then, was not prompted by actual interests but by firm and lasting 
principles and facts. 
Scientific respect, the reputation of Albert Szent-Györgyi as well as his 
devotion to human mankind, progress and science and his sense of responsibility 
justify our wish. As John T. Edsall wrote in his obituary: "Albert Szent-Györgyi was 
a scientist and an incomparable humanitarian man". Szent-Györgyi himself wrote 
in his autobiography: "never has the World known an era more whirling than this, 
therefore, there has to come a paramount change in our ideas as well." "For me" he 
wrote "it is clear what this change is: It is a transition from a pre-scientific into a 
scientific era which is not only a fundamental change, but it has come unexpectedly 
without giving us time to adapt to it." 
In his autobiography Szent-Györgyi wrote: "Is not science about living society? 
1 believe it is. Science is first of all the society of people without any limitations in 
time or space. Science opens unlimited possibilities if we work together instead of 
pushing advantages at the expense of each other. Science has always helped in 
understading and dominating Nature. It will perhaps also help us to comprehend 
ourselves while a new way of human life is being created, the richness and beauty of 
which cannot be described even with the liveliest imagination." 
The lifework and attitude of Albert Szent-Györgyi which have never seemed 
more up-to-date than nowadays, prompted us to decide to rename our University. 
Opening of the Renaming Celebration in the National Theatre of Szeged — by Professor János Szilárd, 
Rector of the Medical University. 
10. 
K Á R O L Y N É M E T H 
Presentation of the renaming document 
Honoured University Council! 
Ladies and Gentlemen! 
I have the honour. to greet all the Hungarian and foreign guests at this 
celebration. I wish to convey the.best regards of our state and party leadership to the 
community of Szeged University of Medical Sciences. 
I highly appreciate the kind invitation, and I am glad to have the opportunity to 
participate and contribute to this very important event in the life of the University. 
It is a great honour for me to have the pleasant duty of presenting the document 
entitling the University to use the name of Albert Szent-Györgyi — according to 
your wish. 
The presidium of the Hungarian People's Republic readily supports this 
intention and believes that this renaming will also meet the concensus of the public. 
The name, the life work and the memory of Albert Szent-Györgyi are highly 
esteemed throughout Hungary. He remained loyal to his town and country 
declaring himself Hungarian, even when he lived.and worked in the United States 
of America. 
Efforts to serve mankind as well as affection towards his country were his main 
intentions. In his public and scientific activities alike he was always led by feelings of 
responsibility and humanity. I consider that this mentality is still worth following 
nowadays. 
Honoured Guests! 
It is now fifty years since Albert Szent-Györgyi received the Nobel prize. On 
the occasion of this remarkable Anniversary I present to you this document 
entitling the University to bear his name. I wish you to continue your work in his 
spirit, further enriching the results achieved so far and striving, at the same time, to 
benefit our people and country. 
In this special hour I wish to greet all the staff and students of the University 
which bears here and now the name of Albert Szent-Györgyi. I wish you health, 
peaceful and constructive work. 
Thank you for your attention. 
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Károly Németh, the President of the Presidium presents the renaming document to Professor János 
Szilárd, Rector 
10. 
P R O F E S S O R B R U N O F. S T R A U B 
Remembering Albert Szent-Györgyi 
Honoured Guests! 
It is known that his years as professor in Szeged were the peak of Albert 
Szent-Györgyi's career and influence. An occasion like this — that is, when I have 
an opportunity to talk about my Master — is always a responsible and honorable 
duty. 
This day, when Szeged University of Medical Sciences is being renamed Albert 
Szent-Györgyi University, not only has confirmed that he is one of the greatest sons 
of our country, but also that the University wishes to continue his work towards 
progress in science, congnition of truth, the training and education of the young, 
and cultural development in Hungary. 
As a disciple and freshman I was lucky to work with him just at that period. 
Allow me to talk about my personal memories and how the University — first of all 
students — can and should follow his lead. 
I was eighteen when Albert Szent-Györgyi asked me, a first year student, 
whether I felt like working at his Institute. During the years of training he checked 
my work personally, and in the next laboratory I could see myself how he worked 
with his co-worker dr. Ilona Banga. I am not going to talk about professional 
memories but about him as a human being. 
The Professor talked to me as well as to other young research workers as if we 
had been his equals. And it was easy to get used to this and follow his example. 
In the beginning of the 30's from a formal, hierarchic and authoritative 
atmosphere I entered a wonderful new world. Respect here was paid to one's work 
and human values and not to one's rank. 
With the passing of years, we the younger generation started to contribute to 
the progress of research in the Department and two new elements could be 
observed. These were in contrast with those prevailing at other neighbouring 
Departments in Dom square. One of these elements was that whenever a new result 
was achieved Szent-Györgyi asked me to set it down in the form of a scientific 
paper. After long contemplation and "gnawing on the end of my pencil" I prepared 
the article and presented it to the professor. After a couple of days he gave the paper 
back in a form which was definitely more intelligible and logic than my original 
version. On the top of the paper my name appeared only, although the original idea 
and the final version of the manuscript came from the Master. One proof of 
Szent-Györgyi's greatness was that he never put his name on any paper the 
experimental results of which were not his own work. After four or five years, 
naturally I also learnt to come up with ideas and then put the results down 
comprehensibly. By then only minor amendments were necessary. 
13 
I feel it important to relate another of my memories. For Professor Szent-Györgyi 
the search after scientific truth, the recognition of hitherto unrevealed facts and 
relationships was a credo, the aim of his life. It happened many times that when he 
arrived in the laboratory in the morning he would immediately start to talk about his 
new ideas with whichever of his co-workers he happened to meet. He never 
expected them to respond merely with a remark on how interesting his idea was: 
rather he wanted to hear objections and arguments. He highly appreciated it if 
someone added new and constructive thoughts to his ideas. This kind of human 
contact, free of any kind of authoritativeness, was the most wonderful and in fact 
the most fruitful way of searching after scientific truth. 
Albert Szent-Györgyi was a man of success. Nobel Prize winner George Wald 
wrote about him recently: "Szent-Györgyi with his life work deserved three Nobel 
prizes". I suppose there have been very few scientists in this century about whom 
this could be said. But whoever thinks that he had an easy life is making a great 
mistake. It was no easy at all. From his youth he had to cope with more and more 
problems. He was really lucky to survive two World Wars. As a beginner he had 
serious financial difficulties after graduating from the University, until he became a 
research worker with a subject of his own in the laboratory of the famous Professor 
Hopkins. When he was invited to the University of Szeged this facilitated him in 
finding coworkers and broadening his research field. Financial conditions, however, 
were not provided and he had to fight for funds. His political view was opposed to 
the class in power and he was always envied and criticised by many. 
Albert Szent-Györgyi was an extremely inquisitive man. He was interested in a 
great many things outside the scope of his research field, such as literature, music 
and the fine arts as well as social and political problems. I shall not go into details, 
since his works and writings are accessible. But in one context I feel it important to 
recall a memory, which may have a beneficial impact on the attitude of our young 
people. 
As the Rector of the University of Szeged during the 2nd World War, he tried 
to introduce a new mentality but very soon after he was forced into illegality. In the 
years after the liberation of Hungary by the Soviets he invested vast energy in 
research management and the reorganization of the Hungarian Academy of 
Sciences. Disillusioned by the policy of the personal cult his fate became the bitter 
life of immigrants. We were happy to welcome him in our country again at the age 
of 80. Then the whole country could witness his wisdom. He had a really hard life 
but nothing could prevent from reaching the peaks of science. The message of his 
teaching — "Only he who fights for the truth again and again, is able to create" — 
will always be remembered. 
14 
Address of Bruno F. Straub. Vice President of the Hungarian Academy of Sciences 
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P R O F E S S O R E N D R E S O M O G Y I 




The Medical Universities of Debrecen and Pécs have conferred on me the 
honour of greeting you on the occasion of this special event. In the history of an 
Institution there is hardly any occasion other than renaming where there is time to 
look back to the past but also for to the future. It means a conscious acceptance of 
life because it means an identity with both the veracities and errors of the 
name-giver. In this context renaming is an intention to regard the name-giver as an 
example, and his memory a spiritual inspiration which remains living and topical. I 
suppose the major objectives in choosing the name of Albert Szent-Györgyi are not 
only a tribute to the past. 
• The name and university background of the Nobel prize winning scientist 
Albert Szent-Györgyi further enhance the scientific and public respect of the 
University on a national and an international scale alike. I believe that Universal 
research is the symbol of the near future and progress of the University. Training, 
medicine and scientific research are the catalysts for the challenges of the 21st 
century; In one of his works Albert Szent-Györgyi wrote the following: "There 
might be differences between the two worlds, namely prescientific and scientific 
eras. It is, however, undeniable that the world of science is also the world of peace." 
This was the guiding principle of the throbbing, ever passionate life of Albert 
Szent-Györgyi. It is also witnessed by his own thoughts when he declares: "Looking 
Báck on my past I see that I have been seeking peace during all my eventful life." His 
scientific and public projects thus always merged. 
Albert Szent-Györgyi's Szeged citizenship also involves his nationality and 
interriationality.Tt also involves the fact that he used to be a professor of the Péter 
Pázmány University of Sciences, and at whatever stage he could he co-operated 
with Hungarian medical universities. This attitude led later to the pressure-born 
idea of establishing a laboratory free of walls, which became one of the greatest 
spiritual ventures of the 20th century and a means of cooperation between 
top-ranking research institutions. 
Some of us present in this room might consider ourselves lucky to have had the 
possibility to become acquainted with Albert Szent-Györgyi not only through 
stories and writings but personally. For some of us he was our teacher or colleague, 
for others an intellectual partner as well. It is foreseeable that some features of his 
portrait will change along with the historical perspectives, certain elements will be 
stressed and others ousted. I assume, however, that the paramount impact of the 
personal contact, the indirect memories mean an inner strength which might initiate 
expected social and scientific changes. 
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I do not intend to talk about the scientific results of Albert Szent-Györgyi, 
since numerous books and papers have been published on them. I would rather say, 
that choosing a name puts one under obligation and we respect the University for 
this decision: it is a privilege for the Hungarian medical community to live with the 
memories of Albert Szent-Györgyi. We hope the idea of a laboratory without walls 
will further connections not only at international level but also between Hungarian 
medical universities. 
With these thoughts I wish for successful work worthy of the name-giver in 
training, medicine and scientific research on behalf of the Medical Universities of 
Debrecen, Pécs, the Institute for Medical Postgradual Training and my own 
Institute the Semmelweis Medical University of Budapest. 




P R O F E S S O R K L A U S K Ü H L 
On behalf of Medical Universities abroad 
Hochverehrter Herr Staatspräsident! 
Hochverehrter Herr Gesundheitsminister! 
Hochverehrte Vertreter der gesellschaftlichen und staatlichen Einrichtungen! 
Magnifizenzen! Spectabilitäten! 
Meine sehr verehrten Damen und Herren! 
Es its eine grosse Auszeichnung, dass ich als Vertreter der Ernst-Moritz-Arndt-
Universität Greifswald Gelegenheit habe, mich für die Einladung anlässlich der 
feierlichen Namensverleihung Ihrer Universität im Namen der anwesenden Teil-
nehmer der wissenschaftlichen Einrichtungen des Auslands recht herzlich zu 
bedanken. 
Ich bedanke mich damit im Namen des Rektors der Medizinischen Akademie 
Odessa sowie im Namen der Rektoren der Universitäten Olomouce, Ulm und 
Greifswald. 
Mit Freude sind wir Ihrer Einladung gefolgt, um Ihnen zu der feierlichen 
Namensverleihung unsere Glückwünsche zu überbringen. Als Vertreter der 531 
Jahre alten Ernst-Moritz-Arndt-Universität Greifswald bin ich stolz darauf, dass 
unsere beiden Universitäten seit 1971 durch den somit ältesten Freundschaftsvert-
rag verbunden sind. 
Der ehrenvolle Name des Biochemikers Albert Szent-Györgyi, dem für seine 
Arbeiten über biologische Verbrennungsprozesse, 1937 der Nobelpreis für Medizin 
verliehen wurde, ist Würdigung und Verpflichtung zugleich. Dieser Name soll uns 
Richtschnur für das Erbringen weiterer hoher Leistungen auf dem Gebiet der 
medizinischen Lehre, der medizinischen Forschung und der medizinischen Betreu-
ung in einer Welt des Friedens sein. 
Magnifizenz, werte Anwesende, mögen unsere freundschaftlichen Verbindun-
gen ganz im Sinne des Nobelpreisträgers Szent-Györgyi dazu beitragen, die 
medizinische Wissenschaft voranzutreiben, um immer bessere diagnostische und 
therapeutische Verfahren für eine immer besser werdende Betreuung unserer 
Patienten zu entwickeln. 
Mögen unsere gemeinsamen Bemühungen dazu beitragen, an unseren hohen 
Schulen Studenten auszubilden, die wir — mit einem soliden Fachwissen und 
praktischen Fähigkeiten ausgestattet — in ihr späteres Berufsleben als Ärzte, als 
Wissenschaftler oder als Hochschullehrer entlassen können. 
Zur Lösung dieser anspruchsvollen Aufgaben wünsche ich Ihnen, Magnifizenz 
Prof. Szilárd und Ihren Mitarbeitern Gesundheit und Schaffenskraft. 
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10. 
P R O F E S S O R J Á N O S S Z I L Á R D 
Presentation of the 
"Albert Szent-Györgyi Commemorative 
Medal" to Professor Ilona Banga 
The Council of the Medical University of Szeged at its 3rd regular meeting 
founded an "Albert Szent-Györgyi Commemorative Medal" to be presented for the 
best research results achieved. 
According to the rules of presentation "the Council of the Albert Szent-Györ-
gyi Medical University to commemorate the Nobel prize winning Professor decided 
on the foundation of the Albert Szent-Györgyi Medal to be presented in acknowled-
gement of outstanding scientific work done for the benefit of the health of mankind 
and for better cooperation and understanding. 
Proposals for the decoration can be made every other year. Persons recommen-
ded can be Hungarian and foreign alike, who have achieved outstanding results in 
the field of medical science and promoted better human understanding". 
Our University wishes to present the first medal to professor Ilona Banga. 
Professor Ilona Banga (wife of Professor József Baló), doctor of biological 
sciences, studied at the Universities of Szeged and Vienna. She obtained her 
doctor's degree in 1929, then conducted research in enzymology at the Department 
of Medical Chemistry and physiological studies with professor Verzár at the 
Department of Physiology of Debrecen. 
Ilona Banga was recommended to Albert Szent-Györgyi — with whom she 
worked for 17 years — by her professors at the beginning of the 30's, the first 
pioneering era of the Department of Medical Chemistry of Szeged Medical 
University. The main research project at this time was carbohydrate metabolism. 
The second pioneering era of the Department headed by Albert Szent-Györgyi was 
between 1940—44. The common research work of Albert Szent-Györgyi and Ilona 
Banga resulted in the discovery of actin and its isolation from actomyosin. The 
isolation and characterization of actin are due to the merits of Professor Straub. As 
to the significance of these research results they would have deserved another 
Nobel prize if the years of the Second World War had not prevented their 
publication abroad. When Albert Szent-Györgyi and his male colleagues had to 
escape to avoid drafting and Nazi persecution, Ilona Banga remained at the 
Department and thanks to her courage the Deparment of Medical Chemistry was 
the only institution of the University where all the equipment and facilities were 
preserved, including the entire stock of the Klebesberg Library. During the years 
following the liberation of Hungary by the Soviets, Ilona Banga worked in 
Budapest. Arteriosclerosis research was her main field of interest and she 
discovered and isolated elastase, an enzyme dissolving the elastic fibers in walls of 
blood vessels. For the results of this research project she and her husband József 
21 
Baló were awarded the Kossuth Prize in 1955. In the ensuing years she studied 
connective tissue of blood vessel walls and its changes during the aging process. Her 
books aroused great interest not only in Hungary but abroad as well. 
With these words I wish to present the Albert Szent-Györgyi Commemorative 
Medal to Professor Ilona Banga with the highest respect and appreciation. 
22 
10. 
Conferment of the degree 
of doctor "Honoris causa" 
P R O F E S S O R J Á N O S S Z I L Á R D , Rector of Albert Szent-Györgyi Medical University 
We wish to continue this renaming celebration — following the old traditions 
of our University — by conferring degrees of doctor "honoris causa" on four 
outstanding scientists from abroad. 
I sincerely welcome in our town and University • /• 
Professor SERGE BONFILS 
Professor EGON DICZFALUSY 
Professor HELMUT KALA ' • 
Professor JOACHIM WOLFF . " 
I am happy to inform you that the Council of the Szeged University of Medical 
Sciences at its meetings held on June 20, 1986, December 19,1986 and on June 19,. 
1987, respectively, decided to confer the degree of doctor "honoris causa!' for your 
internationally acknowledged results in the medical and.pharmaceutical sciences 
and for furthering the contacts between our Universities. 
Now I invite the Deans of our University to outline the main landmarks in the; 
career of the candidates for the degree of Doctor "honoris causa". 
PROFESSOR GYULA TELEGDY, Dean of the Medical Faculty at Albert 
Szent-Györgyi Medical University. 
Professor SERGE BONFILS has been working at the Faculty of Medicine at 
the University of Paris since 1945. In 1970 he was appointed head of the Internal 
Department of the Hospital Bichat. His predecessor and teacher at this department 
was Professor Lambling, who is regarded as the greatest living French gastroen-
terologist. 
Professor SERGE BONFILS is the leading personality in French Gastroen-
terology. Until 1984, besides running the Department of Internal Diseases, which 
focuses particularly on gastroenterologic problems, he also performed the duties of 
director of the INSERM (U.10) Research Institute. Since 1984 he has continued in 
charge of the clinic, but as the leader of his research team he participates in the work 
of the Research Institute, now functioning under the leadership of one of the 
members of the school he has created. In 1983 he was the president of the French 
Gastroenterologic Society. At present he is the active vice-president of the 
gastroenterologic World Organization (OMGE). Besides the French Gastroen-
terologic Society, gastroenterologic societies abroad (e.g. in the USA and England) 




Candidates for the degree of doctor "Honoris causa" and representatives of universities. 
Hungarian Gastroenterologie Society in 1985. His scientific work is marked by a 
great number of books, publications and lectures. 
Professor BONFILS's connection with Hungarian internists, including gas-
troenterologists, dates back more than twenty years. He has made it possible for 
four internal specialists from our University to take part in one-year fellowships in 
France. With the support of the Cercle André Lambling, founded in honour of his 
predecessor, two clinicians from the socialist countries, both from Szeged, have so 
far been invited to Paris to become acquainted with the achievements of French 
culture. 
Professor SERGE BONFILS is a clinician and researcher of international 
repute. He has visited Hungary several times and has been of great help to our 
University in the course of preparatory work for scholarships and scientific 
co-operation by promoting relations between researchers from Szeged and French 
institutes. Apart from clinicians, organic chemists participating in peptide-research 
have benefited from his support. 
This conferment of the title of Doctor "Honoris Causa" on Professor BONFILS 
is a symbol of the warm scientific relations between Hungary and France. The 
international prestige of our university can only be increased by this award to 
Professor BONFILS. 
Professor EGON DICZFALUSY was born in Miskolc on 19th September, 
1920. He was a student at our university from 1938, and graduated here "summa 
cum laude" in 1944. While a student, he worked, as an assistant at the Instute of 
Pathology and Bacteriology, together with Professor Ivanovics, from 1942 to 1945. 
He then joined the staff of the Institute of Biochemistry. He started his research 
work in Szeged and his first results were published here. In 1946 he moved to 
Sweden, where he continued his work at the Karolinska University in Stockholm. 
He was director of the Reproductive Endocrinological Research Institute of the 
Swedish Medical Research Council from 1967 to 1981, and in 1981 he was appointed 
director of the Department of Reproductive Endocrinology of the Karolinska 
Institute. Furthermore, he is director of the Research Institute of the World Health 
Organization in Stockholm and a leading consultant of the Human Reproduction 
Program of the World Health Organization. 
The main subject of his research work for many years has been human 
reproduction. The term "foetoplacental unit" is associated with his name, and his 
investigations have provided basic knowledge about the hormonal function of the 
placenta. During the past 20 years he has mainly been studying the contraceptive 
aspects of human reproduction. His achievements have been published in more 
than 500 papers. The books written or edited by Professor DICZFALUSY number 
about 20. 
Professor DICZFALUSY is an honorary member of 15 international medical 
societies, including the Hungarian Endocrinological and Metabolic Society and the 
Society of Hungarian Gynecologists. He has been awarded several high-ranking 
medical medals (the Ruth Gray Medal, the Medal of the Barren Foundation, the Sir 
Henry Dale Commemorative Medal, and the Commemorative Medal of the 
Academy of Paris). He has been or is a member of the editorial boards of the 10 
most important endocrinological journals. 
He has always maintained close contacts with Hungarian medicine, and with our 
university in particular. He played a great role in the selection of the Department of 
Gynecology and Obstetrics, University Medical School, Szeged as a World Health 
Organization Clinical Research Center in 1972. He has been an active supporter of 
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the collaboration between this center and the World Health Organization ever 
since. This has meant considerable financial support, besides the scientific achieve-
ments and the fellowships for several research workers from this Department. He 
has been to Szeged several times as a representative of the World Health 
Organization. He has made it possible for more than ten Hungarian researchers to 
spend a one- or two-year fellowship at his institute, the good results of which are 
reflected by nearly 20 joint publications. Several researchers from our university 
have also spent long periods at the Institute of Professor DICZFALUSY or have 
paid him short visits in Stockholm. 
By virtue of his world-famous research work, his close scientific connections 
with Hungary and Szeged in particular, and his constant good will and readiness to 
help, Professor DICZFALUSY, who gained his medical degree at our university, is 
fully worthy of the degree of doctor "Honoris Causa", which is conferred upon him 
by this university. This award to Professor DICZFALUSY is a further sign of the 
continuation of the friendly and fruitful Swedish-Hungarian relations, and it greatly 
adds to the prestige of our university. 
Professor JOACHIM WOLFF was born on 25th March, 1935 in Berlin. He 
graduated from the Medical University of Berlin in 1960. From 1961 to 1971 he 
worked as researcher and lecturer at the Institute of Anatomy. He was then invited 
to Basel, as a guest researcher by the firm Sandoz, where he worked for one year. 
Between 1971 and 1980 he was head of the Neuroanatomy Unit of the Max-Planck 
Institute, Göttingen. Since 1980 he has been director of the Anatomy Institute and 
Developmental Neurobiological Centre of Göttingen University. He has been a 
guest professor in Berlin, Würzburg, Regensburg, Heidelberg, Basel and Sydney. 
For his outstanding achievements in the field of neuroscience, he was requested to 
join the Wissenschaftskollege zu Berlin in West-Berlin for a year. 
Professor WOLFF's scientific activity, the exploration of the vascularization 
developmental mechanism of the cortex and the plasticity of the central and 
peripheral nervous systems, with special regard to his scientific work in the field of 
the induction of neuronal plasticity without lesion, has won international appreciati-
on. The results of his research work have been published in a great many books and 
in more than 200 scientific papers. He is internationally recognized for his scientific 
achievements, and received an honorary doctorate from the University of Göteborg 
in 1978. 
He is a member of many scientific societies, for instance the International 
Brain Research Organization, the European Neuroscience Association, the Inter-
national Society for Developmental Neuroscience, the International Society for 
Stereology, the Anatomische Gesellschaft, and the Deutsche Naturforscher und 
Arzt-Gesellschaft. 
Professor WOLFF is always willing to work together with Hungarian resear-
chers. His connections with our country and particularly with Szeged date back 
more than a decade. During that time he has received 18 Hungarian researchers, 
who have spent altogether 16 years at his institute. 
On this basis, and in the knowledge of Professor WOLFF's affection for 
Hungary, we can be sure that, by conferring on him the degree of doctor "Honoris 
Causa", we are strengthening the long-established Hungarian — West-German 
connections. This award further enhances the reputation of our university. 
On the basis of all that has been put forward. I, Gyula Telegdy, university 
professor and Dean of the Medical Faculty, confer the degree of Doctor "honoris 
causa" upon 
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Professor SERGE BONFILS 
Professor EGON DICZFALUSY and 
Professor JOACHIM WOLFF 
and confer on you all the rights due to honorary doctors according to the rules and 
customs of our university. 
I wish that you, in the possession of the highest decoration our university can 
give, have the strength to strive towards the enrichment of your research field and 
the successful training of the next scientific generation for the benefit of science and 
mankind. 
PROFESSOR BÉLA SELMECZI, Dean of the Faculty of Pharmacy at the 
Albert Szent-Györgyi Medical University 
Professor Dr. HELMUT KALA was born on 18 th January, 1926, in Kreisfeld. 
After receiving his degree in pharmaceutics in 1953, he worked as a research 
assistant at the Pharmaceutical Institute of the Martin Luther University in Halle. 
Here he received his university doctorate, after which he was appointed first 
research assistant and was invited to lecture on drug analysis and drug technology. 
In 1963 he became a lecturer, in 1964 associate professor and in 1967 full professor. 
Two years later he was appointed head of the Drug Technology Institute of the 
Pharmaceutical Faculty. 
As a distinguished scientist in the field of pharmaceutics, in 1971 he received 
the title of Academic Doctor of Sciences. 
Professor KALA's scientific work has always been characterized by co-opera-
tion with the pharmaceutical industry. In recognition of his scientific research, he 
has been awarded the Research Prize of the Martin Luther University three times. 
In 1981 he received the Thomasius Medal. 
Four of his students have been appointed university professors. He has so far 
produced over 150 publications and 15 patents. He has participated in numerous 
conferences in his home country and abroad, ranging from Paris to Cairo, where he 
has reported on pharmaceutist training in the GDR and on his own world-famous 
research. 
Professor KALA has always placed special emphasis on international co-
operation. Thus, he has carried on intensive and fruitful co-operation with the Drug 
Technology Institute in Szeged for 20 years. He and his colleagues spend one month 
in Szeged every year, exchanging working methods and lecturing. 15 publications 
have so far resulted from this co-operation. The staff of the Szeged Drug 
Technology Institute have all visited Professor KALA's institute on study tours or 
to exchange working methods on several occasions. 
Besides his outstanding educational work and scientific research, Professor 
KALA has always taken an active part in community and civic work. While still an 
associate professor, Professor KALA was elected to the Pharmaceutical Scientific 
Committee, where he was President of the Training and Educational Board for 10 
years. For almost 20 years he worked as deputy director of the educational section 
of the Pharmaceutical Department. He has been a member of the Presidium of the 
Drug Technology Panel of the Pharmaceutical Association of the GDR for 10 
years. He is one of the founders of the Special Drug Technology Committee of the 
Berlin Medical Graduate Academy. In this position he has worked actively in the 
field of training specialist pharmacists. For 10 years he was president of the 
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Revisional Committee of the Pharmaceutical Association of the GDR. In 1971 the 
Ministry of Health of the GDR awarded him the title of pharmaceutical chief 
counsellor. 
In honour of his achievements, he has received numerous awards, among them 
the Döbereiner Award, the Hufeland Silver Award, the Carl-Wilhelm-Scheele 
Prize and the golden Award for Service to Public Health and Social Work. 
Professor KALA's scientific accomplishments are known and recognized 
throughout the world. His professional and personal relationships in Hungary, and 
especially Szeged, have proved fruitful and permanent, and he is undoubtedly 
worthy of the conferment of the degree of doctor "Honoris Causa" by our 
university. 
On the basis of all that has been put forward, I, Béla Selmeczi university 
professor, Dean of the Faculty of Pharmacy at the Albert Szent-Györgyi Medical 
Univesity, confer the degree of Doctor "Honoris causa" upon 
Professor HELMUT KALA 
and confer on him with all the rights due to honorary doctors according to the 
rules and customs of our University. I wish that you, in the possession of the highest 
decoration our University can give, have the strength to strive towards the 
enrichment of you scientific field and the successful training of the next generation 
for the benefit of science and mankind. 
After the conferment Professor János Szilárd Rector of the Albert Szent-Györ-
gyi Medical University greeted the new honorary doctors of the University. 
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10. 
P R O F E S S O R E G O N D I C Z F A L U S Y 
On Behalf of the Newly Accepted Honorary 
Doctors of the University 
Magnifice Rector, Arade Medlemmar is Universitetsstyrelsen, 
Mina Damer ach Herrar! Honoured University Council! 
Ladies and Gentlemen! 
I have been honoured with the duty of expressing our gratitude for this high 
decoration on behalf of all four of us. Not long ago, about 200 years before, during 
the French Revolution, Jean Baptiste Coffinhal backed up by the Convent signed 
the death penalty of the famous chemist Antoine Lavoisier in 1794, with the 
following remark: "La république n'a pas besoin de savants" — "The republic has 
no need for scientists". In the same year Georg Christoph Lichtenberg drew the 
following character of one of his professor colleagues in Königsberg: "Der Mensch 
hatte so viel Verstand, dass er fast zu nichts mehr in der Welt zu gebrauchen war" — 
"Man is so clever that he is of no further use at all any more." 
Much water has flown under the bridges since then, and the modern society of 
nowadays has recognized the need for a world with scientists after all, and scientists 
have also realized that modern science has essential social dimensions. Forty years 
ago on 10th December I heard a Swedish statement on scientific research, at a 
Nobel Prize awarding ceremony that I have not been able to forget ever since 
"Förskning ar det lidelse fulla sökanaet efter del liderlse fria sanningen" — 
"Research is a zealous search after a stoical truth". In think that modern medical 
research has an even higher level of ambition than that, since over and above the 
search for truth, the target is to relieve human suffering and to improve the quality 
of human existence. 
In this context, we, the first doctors "honoris causa" of the Albert Szent-Györ-
gyi University, wish great success in this endeavour. We hope we have many years 
of further fruitful cooperation ahaead of us for a better future. 
Magnifice Rector, honourable University Council, Ladies and Gentlemen. 
Now I have to meet a honouring obligation. In a few hours, this afternoon, on the 
Anniversary of the birth of Alfred Nobel, the Nobel prize winners of 1987 will take 
their prizes from the hands of King Charles Gustav. That is why Professor 
Samuelsson Bangts, Rector of the Karolinska Institute — who is himself a Nobel 
Prize winner — entrusted me to represent him and the Karolinska Institute, and 
pass on the warmest greetings of the Institute as well as those of the Nobel 
Committee and their best wishes to the future activities of the Albert Szent-Györgyi 
University*. 
* Translated from Hungarian 
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10. 
P R O F E S S O R JÁNOS S Z I L Á R D 
Closing Speech 
I wish to express my grateful thanks to Professor Diczfalusy for his most kind 
words and special thanks for the message of Professor Samuelsson. I believe that 
contact between the four new Doctors "Honoris causa" and our University and 
Hungarian medical science may be a modest acknowledgement of their activities, 
but it may be a little more than a modest sign of our University's intention to act in 
the spirit and principle of Albert Szent-Györgyi as already acknowledged by the 
Nobel prize Committee 50 years ago. 
As we approach the end of this ceremory, allow me to thank our doctors 
"honoris causa" of former years: Professors Paul Bacsich, László Lajtha, Otto 
Prokop, G. Wooler, David de Wied, as well as the Heads of our Fellow 
Universities, Professor A. Rousi Rector of the Turku University, Professor N. 
Kamp President of Göttingen University who due to other obligations were unable 
to be present but sent their best wishes by letter. These greetings and attentions as 
well as the response to our renaming in geographically distant countries, indicate 
that this day and event is an important contribution in the enhancing of our 
University's reputation and also in strengthening and extending our scientific 
contacts on Hungarian and international levels alike. 
As we arrive at the end of our renaming celebration I wish to thank Károly 
Németh as well as all of those who have graced our celebration with your presence. 
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Opening of the banquet. Professor Gyula Telegdy dean of the Medical faculty, Mrs. Albert 
Szent-Györgyi, János Szilárd, Rector, Károly Németh President of the Presidium, Professor Ilona 
Banga, Professor Béla Selmeczi, Dean of Pharmacological Faculty. 

II. UNVEILING OF THE BUST OF ALBERT 
SZENT-GYÖRGYI IN THE 
SZEGED PANTHEON IN DOM SQUARE 
llth December , 1987, 




MRS. JÓZSEF M Ü L L E R 
Inauguration Address 
Honoured Guests! 
It is 50 years now that on 1st December, 1937, the Nobel Prize winning 
scientist, Albert Szent-Györgyi, became a freeman of the city upon the decision of 
a special assembly of the Szeged City Council. And now, by inaugurating his bust 
here on the wall of the national pantheon in Szeged, among the great figures of 
Hungarian history, science and culture, we wish to manifest our respect and 
gratitude towards this outstanding and fine man. Szeged is the only town in our 
country privileged to have a Nobel prize winning citizen: a scientist, who achieved 
the results of the research for which he was decorated here in this town, using in his 
work a special product of this region, the green pepper. Szeged certainly has much 
to be thankful for to Albert Szent-Györgyi. The town became known throughout 
the world overnight, and also the fact that this important scientific work was being 
conducted here in Szeged to the benefit and in the interest of mankind, as is still the 
case. I suppose it is justified that we Szeged citizens — knowing that we can thank 
the genius of this scientist for these outstanding research results — are especially 
proud of Albert Szent-Györgyi and we regard his activities in our town as an 
important landmark in the history of science and education. 
"I went to work in Szeged" he wrote once "The conditions were provided: 
co-workers, laboratories. All I needed was peace and quiet, and I got it". When in 
October 1973 he returned, unfortunately for the last time, and his former university 
conferred the degree of doctor "Honoris causa" on him, he expressed his 
attachment to Szeged — his home town for 15 years — in the following words: "I 
was happy to come home again, to see the places where I used to live and work. I 
wanted to meet old colleagues and also to see what has become of my former 
students. My homecoming had, however, another aim, namely to recharge the 
"batteries" of my emotions. I wish to strengthen the links attaching me to Hungary 
and Szeged University." This feeling was mutual. The question may arise in us: 
What is it that maintains this sincere interest? It is surely not mere local-patriotism 
or pride, that this great figure of universal science was connected with our town. It 
is much more, I think: the personal magnetism of an extremely colourful, 
renaissance-type personality and a spirit with universal thoughts and problems. His 
extraordinary popularity can be attributed to his humanistic attitude, and the purity 
and wisdom of his spirit. He declared that science should serve man and mankind. 
We all know that he was led by this principle throughout his long and rich life. This 
is an attitude which can be called humanistic but it can be also regarded as a policy. 
When in 1937 he was on his way to Sweden to receive the Nobel prize he said in an 
interview to Népszava (Voice of the People): "Men of science are most worried 
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about peace throughout the world. All our efforts will be in vain if our discoveries 
are being used as tools of destruction, and fruit of our peaceful work will be 
diminished by a world war. The political tension nowadays is frightening, though 
there would be enough bread and space for everyone, if we could properly accept 
each other." 
I think that we who pay homage to him in front of his bust know that Albert 
Szent-Györgyi not only talked about his principles but was ready to act for his 
country and people if needed. Therefore, we know we have an example to follow. I 
hope this bust will make all of us remember it. When we pass it in our everyday life, 
we should remember that we are indebted to him, to this country and to mankind. 
And we should also keep in mind that our University bears his name from now on. 
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Bust of Albert Szent-Györgyi carved by György Kalmár sculptor 
10. 
P R O F E S S O R F E R E N C G U B A 
Fellows' Reminiscence 
We are gathered here to raise a monument to Albert Szent-Györgyi whose 
name our university bears, close to the place where he worked so successfully. 
The magnificence and warmth of our celebration is increased by the presence 
of the members of Szent-Györgyi family, besides the leaders, lecturers and students 
of the University and Szeged citizens devoted to the Professor. Raising the bust at 
this very place has a double significance. The arcades of Dom square buildings 
provide a place for the pantheon of Hungarian intellectuals, where monuments 
remind us of the greatest Hungarians who were pioneers of culture and eternal 
human progress: founders of Universities, writers, poets, scientists. Albert Szent-
Györgyi the Nobel prize winning biochemist is worthy of his place among the great 
citizens of our country proving that our town highly respects this creative man. 
This pantheon serves as a pattern especially to young people. Whenever school 
children walk around under the arcades and listen to their teachers' enthusiastic 
words raptly, we can be sure, that our celebration today will contribute to 
development in our country. The actual place where the bust has been put up is 
associated with this thought, that is the entrance to the Department of Medical 
Chemistry. For many years professor Szent-Györgyi went through this entrance to 
his daily work. Lately, we have been talking a lot about his work, and especially 
about its scientific significance. 
Now I would rather speak about him, the affectionate friend and teacher of the 
young. His informal and charismatic personality had always had a great influence 
on the young. From his numerous exemplary activities, we have also inherited his 
principle: that our future is carried on by the young. To teach and educate is a sacred 
act, therefore it should be pursued like activities leading to factual results. He had 
humanistic principles in training, and he liked young people sound in body and 
mind around himself. When raising this bust to professor Szent-Györgyi we put 
ourselves on the side of the humanist he represented not only in words but also in his 
actions. 
•Thank is due to Márton Kalmár sculptor for reflecting in the bust all the spirit 
and pure humanistic strength characteristic of Albert Szent-Györgyi. May this bust 
enrich the Szeged pantheon of the greatest Hungarians and demonstrate to the 
present and future generations that the progress of a nation is based on the esteem 
of human qualities and creative work. 
38 
Inauguration of the bust of Albert Szent-Györgyi in the Szeged Pantheon (Professor András 
Szent-Györgyi and Mrs. Szent-Györgyi on the right-hand side). 

III. SCIENTIFIC SESSION - LECTURES OF 
THE DOCTORS "HONORIS CAUSA" 
At the Medical Education Center of the Albert 
Szent-Györgyi Medical University 




Hormone secreting tumors of the pancreas: 
Some insights into their clinical 
and fundamental interest 
P R O F E S S O R S. BONFILS 
Faculté de Médecine X. Bichat et Hőpital Bichat — Paris 
Clinical and fundamental research have been progressing simultaneously in the 
field of hormone secreting tumors. Concerning fundamental research the interest of 
human endocrine tumors was originally recognized for pituitary and adrenals. For 
non-steroid hormones, the importance of clinical studies was later on disclosed with 
improvement of diagnosis of insulinoma and serotonin-secreting tumors. As far as 
pancreatic tumors are concerned, gastrinomas with the Zollinger-Ellison syndrome 
(ZES) as clinical presentation were as early as 1968 exceptional material for basic 
research in molecular forms of gastrin and in gastric secretion mechanism. 
Gastrinoma or Zollinger-Ellison syndrome (ZES): an elective model (1) 
Clinically ZES (1) is expressed in 85% of cases as a very common disease, 
peptic ulcer. 1/1000 is the approximative prevalence of ZES in patients with 
duodenal ulcer. Diagnosis of ZES is now more easily obtained with better clinical 
recognition, the use of provocative tests (secretin test) and progresses in imagery 
(CT scan, arteriography). Besides therapy with specific drugs, mostly gastric 
antisecretory substances (H2-blockers; benzimidazole derivatives) (2), attempts to 
excise the tumoral process is a major therapeutic orientation. 
Hepatic metastases (HM) are often the only evidence of malignancy in the 
ZES. In a personal series (3) of 144 consecutive ZES cases with a mean follow-up 
period of 50 months, prevalence of HM was 25%. Preoperative imagery gave the 
final diagnosis of HM in only half of the cases. In the other half of the cases, 
diagnosis was obtained by systematic laparotomy. 
HM were responsible for 50% of the 46 non-operative deaths. At 5 years, 5 of 
29 patients (17%) of the synchronous HM group were still alive vs 65% for the 
entire population. 
Results of chemotherapy for HM in Zollinger-Ellison syndrome was recently 
analyzed in the largest published series resulting from a multicentric study (4). 45 
ZES patients were treated by Streptozotocin (STZ) for HM in 12 European, 
American or Australian centers. 
In the majority of the cases, treatment modalities were those proposed by 
Moertel (5). Actually, total STZ dosage was highly variable (median value : 10 
g/sqm, extremes : 2.5—87). Route of administration was intravenous, into the 
hepatic artery or both. 5 FU. was associated in 28 patients, dauxorubicin in 9 and 
tubercidin in 4. 
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Therapeutic effect was appreciated according to OMS criteria, HM size being 
measured by the best imaging technique for each patient (ultrasonography, CT 
scan, arteriography). Objective response was noted in 42% of the cases : 9 complete 
remissions, 10 regressions with a latence of 17 weeks in mean. Stability was noted 
and tumor progression in 13. 
Toxicity was limited to nausea and/or vomiting (84%) and to transient mild 
proteinuria or tubulopathy (30%). 
In conclusion, except insulinoma, ZES is the most frequent presentation of 
pancreatic tumors with hormone secretion. Thus diagnosis is often discussed in the 
presence of ulcer disease and/or steatorrhea. Diagnosis is better suggested by 
routine gastric secretion studies than gastrin measurement, but a provocation test 
with secretin infusion and simultaneous measurement of serum gastrin and gastric 
acidity is the best tool for obtaining diagnosis certainty. Prognosis has been largely 
improved by the development of 1) gastric antisecretory drugs for suppressing the 
harmful situation due to gastric hypersecretion, 2) Chemotherapy of liver metasta-
ses, 3) More ambitious tumor surgery in well-defined conditions. 
As far as basic research is concerned gastrinomas are a source of precious 
material. In this tissue gastrin secretion is very intense and obviously represents the 
major (if not unique) activity of the tumor. Thus, biological studies can be carried 
out either on dispersed tumoral cells from fragment surgically collected from 
pancreatic and metastatic gastrinoma or from cultures. 
Initial by work Lichtenberger et al (6) did not succeed in obtaining either a 
survival time of the primary culture over 6 weeks or an adequate responsiveness to 
hormonal stimulants. 
According to Ellison et al. (7), acute gastrinoma cell dispersion experiments 
allow to measure gastrin concentration in the medium and the pellet in the basal 
state and after stimulation but with a rapid fading in the release. 
In our group (8), starting from tissues of 5 patients (4 pancreas and one liver 
metastasis) successful cultures were obtained with internative passages and a 
survival time of gastrin secreting endocrine cells presently over 5 months. 
Responsiveness of the model to stimulants (DB cAMP, Ca++, bombesin, carbachol, 
secretin, phorbol ester) and to inhibitors (somatostatin) was successfully tested with 
excellent reproducibility and no time-related fading. Immunochemical (immuno-
gold) evidence was obtained in many cases for the structural identities of the 
cultured cells with the initial sampling concerning morphology and hormone 
secretion. Some features of the cell structure exhibit modification, however 
particularly in granule density and shape. 
Multiple-hormone secreting tumors and MEN I (9,10) 
Ectopic hormone production is the phenomenon by which certain neoplasms 
produce hormones not usually produced in significant amount by tissues from which 
neoplasms arise. Pancreatic gastrinoma gives rise to ectopic hormone production 
since gastrin is not normally secreted by the endocrine pancreatic tissue. In this 
condition multiple hormone production (10) is not uncommon: the most frequently 
observed are VIP (5 -10%) , glucagon (10-20%), somatostatin ( 1 0 - 2 0 % ) , PP 
(15-20%) , insulin (20-30%) , ACTH (10-30%). For fundamental research, 
ectopic hormone-producing tumors provide a potential model for investigating the 
control of gene expression, especially the differences between ectopic hormone and 
entopic hormone production. 
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MEN I fundamentally raises the same kind of problems (9). Prevalence in ZES 
is over 25%. Parathyroid involvement is the most frequent (82% of ZES with MEN 
I). The high rate of relapse after parathyroidectomy (in contrast to primary 
adenoma) implies the presence of a systemic stimulatory factor in keeping with the 
diffuse pancreatic lesions constantly observed in ZES with MEN I (at variance with 
sporadic ZES). 
Vipoma or Verner-Morrisson Syndrome: с AMP activation and relevant symptoms 
(11,12,13). 
They are rare tumors and the published cases of the largest series involve no more 
than 200 patients. Neuroendocrine tumors that elaborate vasoactive intestinal 
polypeptide (VIP) in excess are found in the pancreas (90%) and in neural tissue 
(neuroblastomas, ganglioblastomas) of the autonomic nervous system (10%) 
including the adrenal medulla. Single primary neoplasms constitute 80% of the 
pancreatic tumors, but hepatic metastases do occur in about one-half of them; islet 
cell hyperplasia is present in 10 to 20% of the patients. There is good evidence that 
the cellular source of VIP may be the neural cells within the pancreas and/or the 
endocrine cells of the islets (12). Thus there is a dual role for VIP, neural 
modulation and endocrine. The potent endocrine function of vipomas stimulates 
cyclic AMP in the exocrine cells of the gut to produce a massive secretion of water 
and electrolytes into the small intestine that overwhelmes the normal absorptive 
capacity of the colon. Because VIP is a molecular member of the secretin-glucagon 
family, it has endocrine functions similar to secretin, such as increased pancreatic 
bicarbonate excretion and gastric acid inhibition, as well as a glucagon-like action of 
abnormal glucose tolerance. There is also a vasomotor action of VIP that causes 
vasodilatation. 
Thus, the most prominent feature clinically (11,13) is the profuse watery 
diarrhea in volumes often exceeding three liters per day; it may be explosive, 
episodic and may occur even during fasting. The resulting dehydration and 
hypokalemia produce weakness that may progress to hypotension, compounded 
also by the accompanying vasodilatation. Either hypochlorhydria or achlorhydria is 
frequently observed in spite of normal parietal cells being present in the stomach. 
Distended and enlarged gallbladders have been observed. The lethargy seen in 
approximately 50% of these patients may be due in part to the hypercalcemia. 
Increased plasma concentration of VIP is a major argument for diagnosis. 
Vipoma is a model for intestinal absorption and secretion studies (14); an 
increase in adenylate cyclase activity of the enterocytes may be main explanation 
for diarrhea, although other diarrheogenic hormones (PP, PG, calcitonin) might be 
also secreted by the tumor. This biological responsiveness of enterocytes to VIP was 
proposed as a basis for a biossay (13). Paradoxical observation of cAMP stimulation 
of the gastric musoca with acid secretion inhibition is not yet fully understood. 
Somatostatinoma: a suggestive model for the therapeutic use of somatostain 
The syndrome produced by excessive elaboration of somatostatin has been 
designated the inhibitory syndrome because of its physiologic and pharmacologic 
effects of inhibition of the release of insulin, glucagon, gastrin, and cholecystokinin 
(16). Its inhibitory actions on secretin, vasoactive intestinal polypeptide, motilin, 
thyroid-stimulating hormone and growth hormone are not clinically apparent in the 
syndrome. The clinical findings associated with the presence of a somatostatinoma 
include diabetes, cholecytolithiasis, steatorrhea, indigestion, hypochlorhydria and, 
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occasionally, anemia (11,17). Less than 30 patients have been reported to have 
somatostatinomas. 
Here again, pathophysiological studies could be based on cell biology concepts 
(18). Somatostatin receptors are diffused in the body and receptor studies, even on 
isolated cells, could lead to a better understanding of the biochemical background 
(19,20). However adaptation to a greatly excessive release of somatostatin is 
apparently good for a long period of time without endangering life. 
The use of somatostatin in the management of hormone-secreting tumors, 
particularly those located in the digestive tract, was proposed more than 10 years 
ago. The inhibitory effects of somatostatin on the secretion of most gut hormones 
brought high hopes of a beneficial effect of chronic therapy with this type of 
patients. Only recently has the new molecular form, SMS 201-995 (Sandostatin), 
allowed the overcoming of problems in the short duration of action natural 
somatostatins and particularly the requirement of administration by infusion (21, 
22,23). 
In ZES, numerous publications evidenced ability of SMS to decrease serum 
gastrin and acid secretion for several hours after a single subcutaneous injection; 
only recently its practical usefulness in a management scheme, applied over months 
or years, has been tested by our group. Five patients were to treated during 9 to 12 
months. Basal acid output presented a sustained decrease in 4 out of 5 cases, 
allowing ranitidine discontinuation. The serum gastrin level was affected to a 
greater extent showing a mean 87% decrease throughout the treatment period. 
Tolerance of SMS was excellent and we concluded that antitrophic and antigastrin 
properties of SMS could improve the therapeutic efficacy in long-term management 
of ZES (22). 
In VIPoma patients the beneficial action of SMS was readily shown. The 
diminution in the elevated circulation of VIP was probably not enough to explain 
the outstanding clinical improvement. A direct inhibitory effect on the gut (transit 
time, electrolyte absorption, jejunal secretion) has to be hypothesized (24). 
Exciting aspects of these therapeutic effects of SMS 201-995 were the shrinkage 
of the primary tumor or hepatic metastases in a minority of patients (25,26). It is too 
early to conclude whether this anti-tumor effect of the analogue will contribute to a 
prolongation of the survival of these patients. 
The future of SMS use would probably become clear after receptor studies (27) ' 
giving prevision on the usefulness and the efficacy of this promising hormonal 
therapy. 
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1. 
An Aging Mankind in a Fragmented and 
Integrated New World 
P R O F E S S O R E G O N D I C Z F A L U S Y 
Karolinska Institutet, Stockholm, Sweden. 
Magnifice Rector, excellentissime Decanus, Members of the Senate, ladies 
and gentlemen! To live to see the day, when your old Alma Mater confers on you its 
highest distinction, an honorary doctor's degree, is a very exceptional privilege 
given only to a few in this life and the occasion fills me both with gratefulness and 
with humbleness. 
On a solemn occasion like this, the honorary doctor is expected to look back on 
his scientific career and sum up his contributions. However, to-day is a very special 
occasion ; the day when Szent-Györgyi Albert received the Nobel Prize exactly half 
a century ago. And 30 years ago the same Szent-Györgyi Albert said that there is 
but one safe way to avoid mistakes ; to do nothing, or at least, to avoid doing 
something new. In his spirit, I intend to do something new and instead of looking 
back to my professional life, I will look forward to the great tasks confronting the 
new generation of scientists here and elsewhere. 
In his History of the World, in 1614, Sir Walter Raleigh makes the somewhat 
acid remark that "It is not Truth, but Opinion that can travel the World without a 
passport", which immediately gives rise to the classical reflection: what is truth? 
The Danish Nobel Laureate in physics, Niels Bohr perceived very well the 
complexity of the proposition, when he spoke about two sorts of truth : trivialities, 
where opposites are obviously absurd, and profound truths, recognized by the fact 
that the opposite is also a profound truth, and our times provide many examples of 
this. 
Fifty years ago, as a student of Latin at the Klauzál Gábor reálgimnázium in 
Szeged I came across the well known quotation : Tempora mutantur, et nos 
mutamur in illis ; times change, and we change with them. Now 50 years later, I feel 
that we do not change with the same speed as our times. The changes around us are 
accelerating so rapidly that our perception of these changes is lagging more and 
more behind. The real danger is that our perception of the consequences of these 
changes may be affected even more. 
It took mankind a long time, perhaps 300,000 years, or more, to reach the first 
billion ; then growth accelerated and — as you know — we have reached 5 billion 
this year. All projections of the United Nations (UN) indicate that population 
growth will continue at a gradually slower rate until it stabilizes at 11 billion 
sometime around the year 2100. Approximately 90% of this future growth will 
occur in the developing world. 
For the time being, the growth rate is still extremely high in Africa and in the 
Eastern Mediterranean region, and the population density is by far the highest in 







2000 6.15 (4.9) 
2025 8.3 (6.9) 
2050 9.78 (8.4) 
2100 10.87 (9.5) 
Table 1. Population growth until the year 1987 and projected populations until 
2100. Figures in parentheses stand for developing countries. 
During the next 19 years the world population will increase by 1.7 billion; more 
than half of this increase will take place in 10 countries ; in some of them like Nigeria 
and Ethiopia, the population will double during this time. The effect of this growth 
on the already very low economic level remains to be seen. (Table 2.) 
COUNTRY POPULATION IN MILLIONS GNP US$m 
1986 2006 Increase 
India 775 1036 261 260 
China 1074 1320 246 310 
Nigeria 99 200 101 730 
Indonesia 168 228 60 540 
Bangladesh 104 164 60 130 
Brazil 138 196 58 1720 
Pakistan 104 159 55 380 
USSR 281 328 47 n.a. 
Ethiopia 38 79 41 110 
Mexico 81 121 40 2040 
Table 2. Projected population increase between the years 1986 and 2006 and the per 
capita gross national product in 1984 in 10 selected countries. 
What kind of world is then our world to-day? One-third of the households of 
this world are headed by women and women constitute one-third of the world's 
labour force. Women are responsible for nearly two-thirds of the total hours 
worked, receive only 10% of the world's income and own less than 1% of its 
property. — Another unsolved global problem is unemployment. The International 
Labour Organization estimates that between 1980 and 2000 employment must be 
found for 700 million new entrants into the labour force, approximately twice the 
number of the 1960—1980 period. Moreover, a backlog of unemployed and 
seriously underemployed workers need jobs. This group constitutes one-third of the 
existing labour force of 1200 million. 
Paradoxically, when expressed in percentage terms, mankind never had such a 
good life as to-day, but, in absolute numbers, so many never lived in absolute 
poverty, which traps almost one billion people, 20% of the world population. 
Ninety per cent of them live in rural areas ; more than 50% are small farmers and 
almost 25% are labourers without land. 
What can they do? They move to the big cities, and the urban population is 
increasing dramatically in many developing countries. And since it is the poorest 
people who move, the population of the slum areas is also dramatically increasing. 
(Table 3.) 
Country Year 1965 1984 
Argentina 76 84 
Chile 72 83 
Colombia 54 57 
Hungary 43 55 
Libya 29 63 
Mexico 55 69 
Peru 52 68 
Turkey 32 48 
Zambia 24 28 
Table 3. Increase of urban population as per cent of total in 9 selected countries 
between 1965 and 1984. 
Adequate shelter has been universally recognized as a basic human right; 
nevertheless, the W H O points out that the overall conditions of shelter and basic 
services for more than 1 billion of the poor and disadvantaged in developing 
countries is deteriorating rapidly. Furthermore, some 100 million people have no 
shelter at al l ; they sleep in the streets, under bridges, in vacant lots and doorways. 
All UN — projections indicate that urbanization will continue at an increasing 
rate. In 1974 there were only 28 big cities with a population of 4-million, 15 of them 
in the developing world. By 2025 there will be 135 such cities and 114 of them will be 
in developing countries. By 2025, two-thirds of mankind will be city-dwellers. 
The UN High Commissioner for Refugees estimates that there are between 10 
and 15 million refugees in the world. Their number is increasing at a rate of about 
3000 per day ; half of them are children. The top ten countries with the highest 
number of refugees and their gross national products are shown in (Table 4.) I 
doubt that comments are necessary. 
It may perhaps surprise some of you that the number of physically, mentally, or 
sensorially disabled persons in the world is between 340 and 480 million : 7—10% of 
the world population. Some 35% of them live in developing countries. — The state 
of malnourishment is more difficult to assess, since estimates vary with the 
definitions and methods of measurement used. However, the W H O thinks that at 
least 430 million people are affected ; almost 10% of the world population. 
At United Nations Conferences some governments are consistently voicing an 
optimistic view ; they point out that — on the average — fertility has declined, life 
expectancy increased, caloric intake improved, literacy increased, morbidity 
diminished and health care improved. Indeed, this is true. However, the opposite is 
also true. 
We are back to the game of percentages and absolute numbers. The percentage 
of illiterate adults has decreased, but their absolute number increased. 
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Country Refugees GNP 
in thousands 
Pakistan 2,702 380 
Iran 2,300 n.a. 
Sudan 1,164 360 
United States 1,000 15.390 
Somalia 700 260 
Canada 353 13.280 
Zaire 283 140 
China 280 310 
Burundi 268 220 
Tanzania 213 210 
Table 4. The top ten countries with the highest number of refugees as of Jan. 1. 1986 
and their gross national product (GNP) in 1984. (n.a. — not available). 
As you may know this is the UN — decade of safe drinking water and 
appropriate sanitation and — due to major efforts by the W H O and the World Bank 
— by the end of the decade, in 1990, there will be an impressive increase in the 
percentage of adequately covered population. 
Due to the above efforts, it is expected that 1.5 billion people will have access 
to safe drinking water and almost 1 billion to appropriate sanitation. Those still 
unserved will be 1.2 and 1.8 billion, respectively. These figures do not differ from 
those reported before the UN — decade. What has happened? The simultaneous 
population increase has "eaten up" the impressive results. (Table 5.) 
Population covered 
Urban Rural 
Water Sanitation Water Sanitation 
Year Mill. % Mill. % Mill. % Mill. % 
1970 307 65 269 34 158 13 140 11 
1980 509 72 386 54 472 32 206 14 
1985 672 77 518 60 581 36 252 16 
1990 835 79 652 62 688 41 298 18 
Table 5. Drinking water supply: population covered and access to appropriate 
sanitation in developing countries (both excluding China). Absolute numbers are 
given in millions (Mill.) and percentages indicate the ratio of population covered. 
When it comes to health care, the population per physician dramatically 
diminished in the world's most populous countries between 1965 and 1981 ; in 
parenthesis, the USSR and Hungary have the highest number of physicians in 
relation to their population. At the same time, however, a significant worsening 




China 3780 1730 
India 4860 2610 
USSR 480 260 
United States 640 500 
Indonesia 31820 11320 
Brazil 2180 1200 
Japan 970 740 
Bangladesh n.a. 9010 
Nigeria 44990 10540 
Pakistan 3160 3320 
Hungary 630 320 
Ethiopia 70190 88120 
Malawi 46900 52960 
Mozambique 21130 33340 
Uganda 11080 22180 
Table 6. Population served by one doctor in selected countries in 1960 and 1981. 
(n.a. — not available). 
There has been a dramatic increase in life expectancy at birth around the world 
during the past 20 years ; it increased by more than 10 years in many developing 
countries; and the UN projections indicate that by the year 2025, the global life 
expectancy at birth will be 70 years, instead of 55, which was the case 13 years ago, 
in 1974. (Table 7.) 
Country Population Year (millions) 1965 1984 
China 1030 59 70 
India 749 44 55 
USSR 275 74 74 
United States 237 74 80 
Indonesia 159 45 56 
Brazil 133 59 67 
Japan 120 73 80 
Bangladesh 98 44 51 
Nigeria 96 43 51 
Pakistan 92 44 50 
Table 7. Life expectancy at birth in the most populous countries in 1965 and 1984. 
Population as in 1984. 
As a consequence, dependency ratios will also change. To-day there are 91 
children and 6 elderly per 100 adults in Africa and 36 children and 16 elderly in 
Europe. Furthermore, in aging Europe there are 45 elderly people per 100 children, 
the highest ratio in the world. The UN projects that by 2025 as much as 23% of the 
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population of the industrialized countries will consist of people aged 60 or above 
and that in developing countries their number will double from 6 to 12%. 
Already to-day, the life expectancy at birth exceeds 60 years in 98 of the 166 
member states of the WHO, which corresponds to 62% of the 5 billion living to-day. 
As late as in 1950, the global population of the elderly was only 200 million ; 80 
million of them lived in developing countries. By 2025 there will be 1.1 billion 
elderly and almost 800 million of them in developing countries. 
There is a similarly accentuated increase in the number of women approaching 
the menopause ; in 1960, their number was 330 million worldwide ; by the year 2000, 
their number will exceed 700 million. This will have a profound impact on health 
service requirements. Among the disorders associated with aging and the menopau-
se, the major ones are osteoporosis, cardiovascular diseases, musculoskeletal 
disorders, cancer and senile dementia. 
The best statistics are from the United States, where osteoporosis affects an 
estimated 24 million people ; it afflicts half the women over 45 years and 90% of 
women over 75 years. It is the underlying cause of 1.3 million bone fractures each 
year. The annual cost of osteoporosis and osteoporotic fractures in the United 
States in 1985 was between 7 and 10 billion US dollars. 
Of the 1.3 million fractures more than 210,000 are hip fractures; those are 
associated with more deaths, disability and medical costs than all other osteoporotic 
fractures combined. Men are also afflicted : among those who reach the age of 90, 
32% of women and 17% of men will suffer a hip fracture. Most patients fail to 
recover normal activity, and mortality within 1 year approaches 20%. 
For the time being, the only effective method of prevention in women is the 
administration of estrogen — which is not without other problems — in combination 
with calcium and exercise. Many other agents are under study, for instance for 
providing prevention in men. How many women might be affected by osteoporosis 
in developing countries is unknown ; black and Asian ethnicity appear to reduce the 
risk. Epidemiological studies in developing countries are urgently needed in order 
to assess the future needs for health services. 
What about cardiovascular diseases? Of the 51 million people who die annually 
worldwide approximately 25% die of circulatory and degenerative diseases. In the 
industrialized countries the percentage is more than 50%; in addition, almost 20% 
die of neoplasms. 
Recent reports to the WHO indicate a considerable reduction in death rates 
from cerebrovascular and ischaemic heart diseases in certain western countries and 
a disturbing increase in other countries, among others Hungary. The reasons for 
these opposite trends are incompletely understood (Table 8.) 
The same trend can be observed in more than 60 other cardiovascular diseases 
both in men and women. Because of the overwhelming size of the underlying risk 
(almost 15 per cent of all women around the world are at risk), in-depth 
epidemiological studies on the effect of estrogens with or without added progesto-
gens in different populations would be very important. (Table 8.) 
Thirty years ago, Szent-Györgyi addressed the issue of the third largest 
disorder of aging, saying that "Most human suffering, at present, is caused by the 
so-called 'degenerative diseases' — the name standing for 'diseases we don't 
understand and, consequently, can do nothing about". He strongly advocated more 
basic research in this field. Thirty years later the prevalence and pathogenesis of 
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Cardio- Cerebro- Ischaemic 
Country Period vascular heart 
male fern. male fern. male fern. 
Japan 1972-82 - 3 6 - 4 2 - 5 1 - 5 1 - 2 2 - 3 4 
Australia 1971-81 - 3 2 - 3 9 - 3 9 - 4 4 - 3 3 - 3 6 
USA 1970-80 - 2 8 - 3 0 - 4 5 - 4 2 - 3 6 - 3 9 
Italy 1970-80 - 9 - 2 8 - 2 0 - 2 8 + 1 - 2 0 
Sweden 1972-82 - 2 - 2 0 - 2 1 - 2 4 + 5 - 1 9 
Yugoslavia 1971-81 +24 + 13 + 7 - 2 +35 + 1 3 
Poland 1970-80 +31 + 8 +62 +37 + 5 8 + 4 3 
Hungary 1972-82 +33 + 3 +59 +23 + 3 8 + 6 
Table 8. Percent changes in death rates for 40—69 year male and female ( fem.) age 
group from cardiovascular (ICD 390—485), cerebrovascular (ICD 430—438) and 
ischaemic heart diseases (ICD 410—414) during 10-year periods in several 
industrialized countries. ICD-International Classification of Diseases. 
rheumatic and degenerative musculoskeletal disorders and the possible usefulness 
of estrogen therapy are still the big unknowns. 
And the cancer issue? Neoplasms are responsible for at least 5% of all deaths 
in developing countries and almost 20% in industrialized countries. The most 
frequent cancer types in men are those of the lung, stomach, colon and rectum, 
whereas in women the ranking order is breast, cervix and stomach. According to the 
WHO, there has been an alarming increase in lung and breast cancers among 
women in 28 industrialized countries during the past 20 years. Smoking is a 
well-established risk factor lung cancer ; concerning risk factors for breast cancer, 
there still is a great deal of uncertainty (Table 9.). 
Year Growth 
Carcinoma 1960 1980 (%) 
Lung 22,000 66.000 200 
Breast 44,000 74.000 60 
Cervix 23,000 22,000 - 5 
Stomach 84,000 72,000 - 1 5 
Misc. 311,000 442,000 42 
Total 514,000 720.000 40 
Table 9. Cancer caused mortality of women in 28 industrialized countries. 
A few words about senile dementia. Most estimates for the more severe 
degrees of dementia among those aged 65 and over are between 5 and 8% and the 
lifetime cumulative risk of becoming severely demented by the age of 80 years has 
been calculated to be between 15 and 20%. In the United States, more than half the 
total of over I million persons living in geriatric institutions suffer from mental 
impairment and a high proportion of them require either maximum or intermediate 
grade nursing care. 
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Field studies in Western Europe indicate that institutional cases make up less 
than 10% of the total prevalence of psychiatric disorders in people aged 65 and 
above and that even in cases of psychoses and severe dementia less than 20% are in 
institutional care at any give time. 
According to demographic projections, the total number of affected persons 
will increase over the next 50 years by about 50% in the industrialized countries and 
will more than double in the developing countries. Furthermore, the population 
over 80 years of age, which suffers the highest frequency of demential disorders, will 
double in size by the end of this century and the W H O fears that the burden placed 
by the patients on their families and on the health and social services may be greater 
than they can bear. 
Is then the future hopeless? Absolutely not! However, entirely new approaches 
and an intelligent collaboration with the inevitable will be required. The UN 
Conference on Aging expects that, as men and women live to increasingly higher 
ages, major disabilities will largely be compressed into a narrow range just prior to 
death. However, to achieve this, it is inevitable to spend much more on health 
services and on medical research. Only one-third of the 166 member states of the 
W H O spend to-day more than 5% of their GNP on health : figures of this 
magnitude will be grossly inadequate to cope with the health problems of a rapidly 
changing world. 
Hence, it will be inevitable to rearrange the national priorities and spend on 
arms and armaments much less and on health services much more. There is simply 
no viable long-term alternative, and developing countries will soon realize this. 
(Table 10.) 
Expenses Developed Developing 
spent on Countries 
1970 1978 1970 1978 
Arms and Armament 312 345 70 102 
Health 
and Medical Services 126 213 13 22 
Source: UNEP, 1984 
Table 10. Expenses spent on armament and health services (USD M). 
For the same reason, it became easy to answer the question posed by Adlai 
Stevenson at the UN General Assembly 25 years ago : 'Will Man ever recognize that 
his need for his fellow men far outweigh his arguments with them?" Yes, he will. 
There is simply no long-term alternative. And we have to keep in mind, that our 
lifetime represents the first age since the dawn of civilisation in which people have 
dared to think it practicable to make the benefits of civilisation available to the 
entire human race, and what happens to-day in terms of industrialized country 
assistance to developing countries is just the very beginning of a process, which is — 
again — inevitable. 
Am I a naive optimist? A dreamer? Certainly not. I am only consistent. 
Looking back on history, Lesher and Howiek say that 'Eight hundred life spans can 
bridge more than, 50,000 years. But of these 800 people, 650 spent their lives in 
caves or worse ; only the last 70 had any truly effective means of communicating 
with one another, only the last 6 ever saw a printed word, or had any real means of 
measuring heat or cold. Only the last 4 could measure time with any precision ; only 
the last 2 used an electric motor ; and the wast majority of the items that make up 
our material world were developed within the life-span of the eighthundredth 
person, our own generation.' All of us could add something significant to this list, be 
it the airplane, radio, television, the conquest of space, chemotherapy of various 
cancers, bacterial and viral diseases and the eradication of many infectious diseases. 
Most drugs we use to-day have been developed within our lifetime. Thus science has 
radically changed our world; it will change even more the world of next generations 
and will improve the human condition on Earth. The process is inevitable; hence 
there is plenty of hope for the future. 
Ladies and gentlemen, in the final analysis, hope is the quintessence of the 
human condition, and I believe that each of us has many opportunities in this life to 
generate new hope. I also believe that the collection, systematisation and 
dissemination of scientific information and the generation of fresh hope are crucial 
steps toward improving the human condition to-day and to-morrow. This will also 
be the task confronting you, the new generation of scientists. And in your future 
endeavour, please do not forget that medical research is also an essential ingredient 
of our culture. Therefore remember the words of Kodály Zoltán: Culture cannot be 
inherited. The culture of one's forefathers evaporates in a trice if each generation 
does not acquire it over and over again for itself." — I am convinced, that the Albert 
Szent-Györgyi Medical Unviersity will successfully maintain the cultural treasures 





für die Arzneiformulierung 
von 
P R O F E S S O R H E L M U T K A L A 
Institut für Drog Technologie 
der Pharmazeutische Fakultät 
Martin Luther Universität, Halle/Saale, DDR 
Magnifizienzen, Spectabilitäten, meine sehr verehrten Damen, meine Herren, 
liebe Kolleginnen und Kollegen! 
Ich erlaube mir, die Entwicklung der Pharmazeutischen Technologie — vor 
allem für die Jüngeren im Auditorium für die vergangenen 30 Jahre — anhand 
meiner Person deutlich zu machen. 
Meine Generation besaß am Ende des 2. Weltkrieges im Fachgebiet Gelenik 
keine Hochschulausbildung. Die Kenntnisse der Galenik (so hieß die Pharmazeuti-
sche Technologie damals in Deutschland) resultierten aus dem damaligen obligato-
rischen zweijährigen Vorpraktikum. 
Hier erlernte ich das defekturmäßige Herstellen von apothekenüblichen 
Arzneiformen. Der Vorpraktikant hörte, je nach der Qualität des die Ausbildung 
betreuenden Apothekers, vielleicht auch einmal etwas über physikalisch-chemische 
Prozesse bei der Arzneiformung. 
Während der Hochschulausbildung gab es keine theoretische Vorlesung in 
diesem Fach. Einige kleine praktischen Übungen zu Inkompatibilitätsfragen waren 
alles, womit man auf diesem Gebiet der Galenik während des Studiums konfronti-
ert wurde. 
Deshalb betrieb man das Gebiet empirisch. 
Die Ausbildung erfuhr ab Mitte der 50-iger Jahre in der DDR eine grundle-
gende Veränderung. 
Dieses Gebiet war seit dieser Zeit in Theorie und Praxis voll in den 
Ausbildungsgang der Pharmazeuten integriert, wobei zunächst immer noch die 
Herstellung der Arzneiformen im Apothekenmaßstab im Vordergrund stand. 
Als Student war ich in den Vorlesungen von Prof. Dr. Dr. h. c. mult. Kurt 
Mothes fasziniert, der mich in den Fächern Pharmakognosie und Biochemie der 
Pflanzen durch seinen überzeugenden Vortragsstiel begeisterte. So war es nicht 
verwunderlich, daß sich meine ersten wissenschaftlichen Arbeiten mit der Biosyn-
these der Kumarine in Solanaceen befaßten und von Kurt Mothes im Rahmen einer 
Dissertation betreut wurden. 
Nach erfolgter Promotion erhielt ich einen Lehrauftrag für das Gebiet der 
organischen Arzneimittelanalyse. 
Da ich immer der Auffassung war und auch heute noch bin, daß Lehre und 
Forschung eine Einheit zu bilden haben, änderte ich mein Forschungsgebiet. 
Entsprechend meines Einsatzes in der Lehre bei der Ausbildung von Pharma-
ziestudenten, arbeitete ich nun an analytischen Fragestellungen zur Standardisie-
rung von Arzneistoffen und Arzneiformen. 
Diese Arbeiten haben z.T. Eingang in den allgemeinen Teil als auch in 
Monografien für das Arzneibuch der DDR gefunden. 
Ich habilitierte mich mit einer Arbeit zu Standardisierungsfragen von quecksil-
berfreien Diuretica und von Sulfonamiden. 
Ich war mit analytischen Methoden auf dem Gebiet der Arzneistoffe und der 
Arzneiformen bestens vertraut. 
Durch meine Forschungsarbeiten habe ich damals z.B. die IR-und UV-Spekt-
roskopie und die wasserfreie Titration für bestimmte Arzneistoffe und -formen 
nutzbar gemacht. 
Bei der praktischen Ausbildung der Studenten hatte ich mich aber auch über 
Jahre in der Betreuung des galenischen Praktikums für das 5. und 6. Studienjahr 
betätigt. 
So kam ich schließlich als gelernter Analytiker über die Forschungsarbeiten 
auf dem Gebiet der Arzneiformen-Standardisierung 1965 endgültig zur Phar-
mazeutischen Technologie. 
In dieser Zeit verlagerte sich in immer stärkerem Maße die Herstellung der 
Arzneiformen in den halbindustriellen und in den industriellen Bereich. 
Damit mußte sich das Fach endgültig von der oft auf Empirie beruhenden 
Herstellung der Arzneiformen im Apothekenmaßstab lösen. 
Die Palette der Arzneizubereitungen wurde dabei gleichzeitig durch eine 
Reihe von modernen Arzneiformen bereichert und auch für die Zukunft sind 
nutzbringende, effektive Lösungen hier für dieses Gebiet zu erwarten. 
Neue Wirkstoffträger und Hilfsstoffe, neue Arbeitsverfahren und der damit 
verbundene ständige Fortschritt auf dem Sektor der Apparate-, Maschinen- und 
Automatentechnik sowie die kontinuierliche Verbesserung der Methoden und 
Geräte zur Prüfung der Arzneiformen gaben diesem pharmazeutischen Fachgebiet 
ein neues Profil. . 
Damit kam die Erkenntnis zum Tragen, daß ein Arzneistoff erst dann ein 
optimal wirkendes Arzneimittel werden kann, wenn er in geeigneter Weise zu einer 
Arzneiform verarbeitet wird. Gleichzeitig erschließen sich dadurch neue Möglich-
keiten für bereits bekannte Arzneistoffe. 
Dieser Prozeß beruht nicht zuletzt auf der umfassenden Einbeziehung mathe-
matisch-physikalisch-chemischer Grundlagen über Arzneistoffe, Hilfsstoffe und 
industrielle Verfahren und deren mögliche Wechselbeziehungen und auf der 
Entwicklung der Biopharmazie. Alle die damit zusammenhängenden Fragen 
bezeichnen wir heute als den Komplex der Arzneiformulierung. 
Aus diesen Gründen waren wir der Auffassung, daß der alte Name "Galenik" 
für dieses ehemals empirische Arbeitsgebiet nicht mehr zutreffend sei und führten 
dafür als Bezeichnung "Pharmazeutische Tehnologie" in der DDR ein. 
Die Älteren von Ihnen werden sich erinnern, daß ich vor etwa 20 Jahren hier in 
Szeged einen Vortrag zu Fragen der Aufgaben der pharmazeutischen Technologie 
gehalten habe. Ich brachte damals meine Auffassung zum Ausdruck, daß abgese-
hen von der rein technischen und verfahrenstechnischen Seite das Arbeitsgebiet 
Pharmazeutische Technologie eine pharmazeutisch angewandte Physikalische 
Chemie zu sein habe. 
Von dieser Auffassung bin ich nie abgewichen. 
So bearbeitete ich von 1967 zusammen mit meinen Mitarbeitern des von mir 
geleiteten Wissenschaftsbereiches Pharmazeutische Technologie der Sektion Phar-
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mazie der Martin-Luther-Universität Halle im Rahmen von Vertragsforschungsar-
beiten mit der Pharmazeutischen Industrie der DDR Fragen der Arzneiformulie-
rung für feste Peroralia und löste damit die vorher vorhandenen 18 Forschungsvert-
räge dieses Bereiches auf den unterschiedlichsten Gebieten der Arzneimittelfor-
schung ab. 
Konzentriert für die festen Peroralia wurden unter meiner Leitung seitdem 
Optimierungsfragen, neue Herstellungsverfahren, der Einsatz von neuen Hilfsstof-
fen auch hinsichtlich der Erzielung von protrahiert wirkenden Arzneiformen, 
Auflösungs- und Liberationsprobleme der Arzneistoffe aus der Arzneiform und 
andere physikalische und physikalisch-chemische Parameter als pharmazeutisch-
technologisch interessante Parameter bearbeitet. 
Für biopharmazeutisch relevante Aspekte bearbeiteten wir zahlreiche 
Freigabemodelle für in vitro-Untersuchungen. 
Zur gleichen Zeit, also von 1967 an, gedieh eine fruchtbringende Kooperati-
onsarbeit mit einer Arbeitsgruppe um KEDVESSY und SELMECZI des Phar-
mazeutisch-Tehnologischen Institutes der Medizinischen Universität Szeged, die 
sich in ihrer Intensität immer mehr verbesserte und die im letzten Jahrzehnt eine 
vertragliche Basis hatte. 
Es sei mir an dieser Stelle erlaubt festzustellen, daß diese kollegiale Zusam-
menarbeit dazu beigetragen hat, zwischen dem Pharmazeutisch-Technologischen 
Institut der Medizinischen Universität Szeged und dem Wissenschaftsbereich 
Pharmazeutische Technologie der Sektion Pharmazie der Martin-Luther-Univer-
sität Halle-Wittenberg einen echten wissenschaftlichen Erfahrungsaustausch in 
Theorie und Praxis zu bewirken und was nach meiner Meinung wichtig ist: Es sind 
echte, nicht mehr trennbare persönliche Feundschaften zwischen den Kooperati-
onspartnern entstanden, die weit über ein kollegiales Verhalten hinausgehen. 
In der jüngsten Vergangenheit ist die Wirkungsintensität und — Dauer eines 
Arzneistoffes im wesentlichen Maße durch die Arzneiformen beeinflußbar gewor-
den. 
Immer stärker wird sowohl bei der Grundlagenforschung als auch bei der 
angewandten Forschung die Zusammenarbeit der Pharmazeuten mit anderen 
Naturwissenchaftlern, mit Medizinern und Technikern, insbesondere auch aus den 
Bereichen der pharmazeutischen Industrie, zunehmen. 
Aus der Sicht des Pharmazeutischen Technologen sind bei der Entwicklung 
einer Arzneiform im Hinblick auf die biologische Verfügbarkeit, auf die Verträg-
lichkeit, auf die Stabilität, auf die kontrollierte Wirkstoffreigabe und auf die 
Reproduzierbarkeit, sechs Parameter für den jeweiligen Wirkstoff zu optimieren: 
1. Applikationsart 
2. chemische Form des Wirkstoffes 
3. physikalischer Zustand des Wirkstoffes 
4. Applikationsform 
5. Grund-und Hilfsstoffe 
6. Herstellungstechnologie 
Bei der Entwicklung von festen peroralen Arzneiformen lassen sich nun 
prinzipiell 3 Phasen unterscheiden: 
1. Präformulierung 
2. Formulierung 
3. Scaling up 
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Die optimale Entwicklung von peroralen Arzneiformen (Tabletten, Dragees, 
Kapseln) mit hoher Bioverfügbarkeit und kontrollierter Wirkstoffreigabe erfordert 
im Rahmen der Präformulierungsphase die Erarbeitung von physikalisch-
chemischen Daten für die Wirksubstanz allein, evtl. auch in Kombination mit zu 
verwendenden Hilfsstoffen. 
Zu diesen sogenannten Grundinformationen gehören Stabilitätsdaten, die 
chemische Arzneistoff-Hilfsstoff-Kompatibilität und die physikalisch-chemischen 
Eigenschaften des Wirkstoffes, wie da sind: 
— Löslichkeit, initiale Auflösungsgeschwindigkeit, Auflösung von 
Wirkstoffpulvern (pH-Profil) 
— Partikelgröße, -form, -Oberfläche 
— Polymorphie 
— Benetzbarkeit 





Bei schwerlöslichen Arzneistoffen sind besondere Untersuchungen hinsicht-
lich der Beeinflussung der Lösungseigenschaften durchzuführen und evtl. Möglich-
keiten zur Verbesserung der Auflösungsgeschwindigkeit bzw. der Löslichkeit 
vorzuschlagen, und zwar besonders in den Fällen, wo die Auflösung des Arzneistof-
fes den geschwindigkeitsbestimmenden Schritt im Prozeß der Liberation/Absorp-
tion bei festen Arzneiformen darstellt. In der Regel gilt dabei, daß bei Arzneistof-
fen mit einer Löslichkeit kleiner als 0,3% die Auflösungsgeschwindigkeit zum 
geschwindigkeitsbestimmenden Parameter für die Resorption und damit auch als 
Folge davon für die pharmakologische Wirkung wird. 
Am Beispiel entsprechender pharmazeutischer Problemsubstanzen, bei deren 
pharmazeutisch-technologischer Formulierung Schwierigkeiten bezüglich ihrer 
pharmakologischen Gleichwertigkeit auftreten können und für die die F O O D and 
DRUG Administration (FDA) eine 193 Wirkstoffe enthaltende Liste veröffentlicht 
hat, untersuchten wir in Kooperation mit dem Pharmazeutisch-Technologischen 
Institut der Medizinischen Universität Szeged in den letzten Jahren die Möglich-
keiten der Beeinflussung des physikalischen Zustandes ausgewählter Wirkstoffe, 
sowie deren Bedeutung für die Herstellung und die Wirkstofffreigabe aus festen 
Peroralia. 
Diese Problemarzneistoffe sind durch folgende Eigenschaften gekennzeichnet: 
1. schlechte Wasserlöslichkeit 
2. niedrige Dosierung 
3. geringe therapeutische Breite 
4. verminderte Freisetzung aus Komprimaten 
Als Bedingung für die wissenschaftliche Bearbeitung der dargestellten Proble-
matik waren aussagekräftige physikalisch-chemische Festkörperuntersuchungen 
notwendig, die in unserem Falle durch nationale und internationale Kooperation 
(Szeged) machbar waren, und für beide Partner eine Erweiterung der Arbeitsmög-
lichkeiten darstellten. Solche Untersuchungsmöglichkeiten waren im besonderen: 
— Röntgendiffraktometrie 
— thermoanalytische Verfahren 
— Rasterelektronenmikroskopie 
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— IR- und UV-Spektroskopie 
— in-vitro-Modelle 
— Für die Verarbeitungseigenschaften nach dem z.B. Direkttablettierung-
sverfahren sind dann noch weiterhin geeignete instrumentierte Tablettenmaschinen 
für die Untersuchungen zur Physik der Tablettierung notwendig. 
Die im Handel befindlichen Wirkstoff- und Hilfsstoffqualitäten aus unseren 
beiden Ländern dienten als Grundlage für die differenzierte Herstellung verschie-
den definierter Kristallmodifikationen von Wirkstoffen als auch röntgenamorpher 
Formen sowie von Feststoffdispersionen nach modernen technologischen Verfah-
ren z.B. der Sprühtrocknung. 
Diese Produkte wurden anschließend hinsichtlich ihrer physikalisch-chemi-
schen und tehcnologischen Eigenschaften untersucht und dem Tablettierprozeß 
unterworfen. 
Da bekanntermaßen durch den Preßdruck und die gleichzeitige thermische 
Belastung Veränderungen des physikalischen Zustandes der verarbeiteten Pro-
dukte möglich erscheinen, war es wichtig, Modelluntersuchungen für diese Festkör-
perumwandlungen zu erarbeiten. 
In der Formulierungsphase der Wirkstoffe zu Tabletten nach modernen 
Direktkompressionsverfahren charakterisieren wir schließlich die Anwendung-
smöglichkeiten von Hilfsstoffen auf der Basis von mikrokristallinen Cellulosen. 
Diese wurden vor einigen Jahren als indifferente Füllmittel, Bindemittel und 
Sprengmittel von uns in Tablettenrezepturen eingeführt, besitzen aber -wie die 
durchgeführten experimentellen Arbeiten zeigen- unterschiedliche plastisch-elasti-
sche Eigenschaften und beeinflussen sowohl den Tablettierprozeß als auch die 
Tabletteneigenschaften und die Wirkstoffreigabe in starkem aber unterschiedli-
chem Maße. 
Die Rezepturoptimierungen für verschiedene Problemarzneistoffe ergaben 
sowohl verallgemeinerungsfähige Aussagen zum "Know how" der Tablettenent-
wicklung, als auch die Notwendigkeit spezieller Untersuchungen in Abhängigkeit 
von physikalisch-chemischen Eigenschaften der verwendeten Wirk- und Hilfsstof-
fe. 
Bei unserer Zusammenarbeit haben wir eine größere Zahl solcher Wirkstoffe 
mit polymorphen Eigenschaften pharmazeutisch-technologisch formuliert und 
mittels der genannten Methoden untersucht. Solche Unterfangen sind sehr aufwen-
dig und lassen sich hier nur punktartig skizzieren. 
Ich möchte das kurz einmal am Beispiel der Polymorphie des Antiepileptikums 
Carbamazepin demonstrieren. 
Dazu ist z.B. die Herstellung unterschiedlicher polymorpher Formen und des 
Dihydrats notwendig, was durch Kristallisation, Temperung und Sublimation 
(siehe Schema 1) erfolgte. 
Schema 1 
Herstellungsmethoden für die Carbamazepin-Modifikationen I, II, III, IV, und für 
das Carbamazepin-Dihydrat 
Die Charakterisierung der gewonnenen polymorphen Formen und des Dihyd-
rates führten wir mit den im Schema 2 enthaltenden Methoden durch. 
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Kristallmodifikationen I, II, III, IV 
Suspensionen in Lösungsmitteln 
g/dl 
1,0 g/dl Toluen jeweils in siedenden Wasserbad 
2,0g/dl Ethylacetat lösen, bei-18°C innerhalb von 
3,0g/dl Aceton 30—40 min rekristallisieren. 
5,0g/dl Ethanol (96% V:V)Kristallebei60 - 65°C vortrocknen 
5,0 g/dl Methanol. Lösungsmittel 
jeweils 100 ml durch 
Vakuumtrocknung entfernen 
Temperierung 
Das Handelsprodukt des Carbamazepins wird in dünner Schicht auf Glasplatten 9 h 
im Trockenschrank bei 140°C erhitzt. 
Sublimation 
Das Handelsprodukt des Carbamazepins wird z.B. auf dem Heizblock des 
Boetius-Heiztischmikroskopes (Typ PHMK 78/1873, VEB Analytik, DDR-Dres-
den) einer Mikrosublimation 4 h bei einer Temperatur von 180°C unterworfen. 
Dihydrat-Darstellung 
Carbamazepin-Kristalle werden in Petrischalen in flacher Schicht bei 100%-iger 
relativer Luftfeuchte in einem Hygrostaten bei 20°C — aufbewahrt. 
Schema 2 
Methoden zur Charakterisierung der nach Schema 2 hergestellten Produkte 
Die Beschreibungen der nach dem Schema 1 gewonnenen Modifikationen und 
des Dihydrates sind im Schema 3 enthalten 
Thermoanalyse 
— Meßsystem: Differential-Scanning-Calorimeter vom Typ DSC 2 Perkin-
Elmer Corp. USA-Norwolk 
— DTA-Apparatur: Netzsch-Modell 404 В (Netzsch-Gerätebau GmBH, D-
Selb) 
— Heiztisch-mikroskopie-Appartur: 
Boetius-Heiztischmikroskop (Typ PHMK 75/1873, VEb 
Analytik, DDR-Dresden) 
IR-Spektroskopie 
— Meßsystem: Beckman IR 12 Infrared Spectrophotometer (Beckman 
Instruments, USA-Fullterton, CA) Specord 78 IR (VEB 
Carl-Zeiss-Jena, DDR-Jena) 
— KBr-Technik: 2—3 mg Carbamazepin / 250—300 mg KBr werden mit 
einer Preßkraft von 100 kN zu einer Tablette verpreßt 
— Nujol-Technik: 10 mg Carbamazepin werden in 2 Tropfen Nujol suspen-
diert. Messung mit Hilfe von NaCL-Prismen 
Röntgendiffraktometrie 
— Philips - Vertikalgoniometer PW 1050/25 (Philips, NL-Eindhoven) 
— Hochspannungsgenerator Müller Mikro 1011 Cu Ka-Strahlung, Ni-Filter, 40 
KV, 30 mA, Zählrohrbewegung 1° min -1 
(=20) 
— Horizontalgoniometer HZG 4 (Kombinat Cári Zeiss VEB Präzisionsmechanik, 
DDR-Freiberg) 
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— Hochspannungsgenerator TUR M 62 (VEB Transformatoren- und Röntgen-
werk, DDR-Dresden) 
CuKa-Strahlung, Ni-Filter, 34 KV, 32 mA, Zählrohrbewegung 0,5° min-1 
(=20) 
Lösungskalorimetrie 
Meßsystem: Isoperiboles Kalorimeter LKB 8700-1 
Precisions Calorymetry System for Reaction and Solution 
Calorymetry 
(LKB Produkter AB, S-Stokholm-Bromma 1) 
Dichtebestimmung 
0,4000 g Carbamazepin-Modifikation werden in die Matrize einer hydraulischen 
Presse gefüllt, der Oberstempel 013 mm eingesetzt, die Substanzsäule 60 s 
evakuiert, dann ein Preßdruck von 737 MPa angelegt und 3 min der Druck 
gehalten. 
Wägung nach Entnahme der Tablette ohne Beschädigung. 
Berechnung des Volumens, man erhält die Dichte nach 
p = m/v 
p = Dichte (kg X mr3) 
m = Masse des Preßlings in kg 
V= Volumen des Preßlings in m? 
Die Überprüfung des Verfahrens erfolgte gegen bekannte Dichten (NaCl, Pheno-
barbital, Sulfathiazol) 
Rasterelektronenmikroskopie 
nach Kohle- und Goldbedampfung werden am JSM / 35 С Scanning Electron 
Microscope (Jeol — Co.Ltd, J-Tokyo) / REM-Aufnahmen angefertigt. 
Schema 3 
Beschreibung der nach Schema 1 hergestellten Produkte 
Modifikation I 
Gewinnung druch: 
Umkristallisation aus Ethanol (96% V: V) 
Temperung 9h bei 140 °C 
Sublimation 4 h bei 180 °C auf dem Boetius-Heizblock 
Schmelzpunkt: 190,5 °C 
Schmelzenthalpie ДНР = 24,2 KJ x moL1 
Modifikation II 
Gewinnung durch: 
Umkristallisation aus Toluen 
Schmelzpunkt 188,4 °C 
Schmelzenthalpie ДHF = 19,0 KJ x moL1 






Umkristallisation aus Aceton 
Die DSC-Kurve weist im Bereich 162 bis 172°C das Signal einer endotherm 
verlaufenden Phasenumwandlung der Modifikation III (Raumtemperaturform) in 
Form I (Hochtemperaturform) auf, die jedoch von Schmelzerscheinungen nicht 
umgewandelter Form III bei 1976°C begleitet war. (siehe Abb. 1) 
Die Umwandlung ist von der Heizrate abhängig. 
Bei einer Aufheizung ^ 5 K x min-1 erfolgt eine vollständige 
Umwandlung von III in I. 
Umwandlungsenthalpie AHq = +2,6 KJ x mol -1 
Die Form I und III zeigen enantiotropes Verhalten (Umwandlungswärmeregel). 
Modifikation IV 
Gewinnung durch: 
Umkristallisation aus Ethylacetat 
Die DSC-Kurve dieser Modifikation zeigt im Temperaturbereich von ca. 130 bis 
148°Ceine exotherme Phasenumwandlung in die Modifikation I an (siehe Abb. 1). 
Umwandlungsenthalpie AH 0 = 1,6 KJ x mol -1 
Das Auftreten des exothermen Umwandlungspeaks zeigt Monotropie zwischen 
Modifikationen IV und I. 
Dihydrat des Carbamazepins 
Beim Aufheizen in der Thermoanalyse registriert man im Temperaturintervall von 
ca. 50 bis 80°C einen breiten Desolvatationspeak (Abb. 1, Kurve D). 
Gravimetrisch läßt sich ein Gewichtsverlust von 13% bestimmen, das beweist das 
Vorliegen des Dihydrates. 
Für die Kristallmodifikationen und für das Dihydrat stimmen die Ergebnisse des 
DSC und der DTA überein 
Die Abb. 1 enthält die DSC-Kurven der polymorphen Formen und des 
Dihydrates des Carbamazepins. 
Wir haben natürlich zur Charakterisierung der Modifikationen auch die 
anderen von mir hier genannten physikalisch-chemischen Methoden benutzt. Im 
Rahmen des Vortrages sind sie aus Zeitgründen nicht zu demonstrieren, für 
Interessenten sei die entsprechende Literatur (2, 3) genannt. 
Um den Einfluß verschiedener bei pharmazeutisch-technologischen Arbeiten 
wirkender Kräfte auf bestimmte Kristallgitter zu untersuchen, unterwarfen wir z.B. 
die Carbamazepin Modifikationen I, II, III unterschiedlichen Preßkräften bei der 
Direkttablettierung. 
Das kristallografische Verhalten untersuchten wir für die resultierenden 
Preßlinge mit Hilfe der Röntgendiffraktometrie, der IR-Spektroskopie und der 
Differential-Scanning-Kalorimetrie. (2) 
Die Kristallgitter der untersuchten Modifikationen weisen gegenüber den 
Preßkräften eine unterschiedliche Stabilität auf, was in der Analogie zur Kraftein-
wirkung durch Mahlungsversuche des Carbamazepins steht. 
Die Modifikation II ist gegenüber mechanischer Belastung (Mahlung, Tabletti-
erung) instabil, die Modifikation I wandelt sich nur unter forcierten Arbeitsbedin-
gungen um. In beiden Fällen entsteht aber die mit 1340 kg/m3 die größte Dichte 
besitzende Modifikation III. 
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Abbildung 1 
DSC-Kurven der Carbamazepin-Modifikationen und des Dihydrates Heizrate 
10 К min-1 
Ж 
dt 
Dagegen wird bei den von uns gewählten Versuchsbedingungen (Kompression 
20, 50, 100 kN) das Kristallgitter der Modifikation III nicht soweit verändert, daß 
sie in eine andere Modifikation übergeht. (3) 
Bei der Preßkrafteinwirkung unter genormten Bedingungen auf die Kristalle 
der Modifikation II trat eine preßkraftinduzierte Modifikationsumwandlung auf, 
die die schon früher von uns getroffene Feststellung, daß unter dem Einfluß der 
Preßkraft eine Modifikationsumwandlung polymorpher Arzneistoffe nur initiiert 
wird, erneut unterstreicht (s.Abb.2). (4) 
65 
Abbildung 2 
Röntgenbeugungsdiagramme für die mit 100 kN verpreßte Carbamazepin-Modifi-
kation II in Abhängigkeit von der 
Lagerungsdauer 
Pulveraufnahmen 
od ^ a a J Í K J J Iii 
14 d Ul 
20 d 
45 d 
J ^ k A Í H ^ 
170 d aJWAJ* 
30 25 20 Ts 10 5 
2€ [•] 
Die Umwandlung ist dabei von der Größe der angewandten Preßkraft 
abhängig, wobei nach unserer Auffassung in Relation zur Preßkraft eine Defektsi-
tuation im Kristallgitter der Ausgangsmodifikation auftritt. 
Mit der Erhöhung des Preßdruckes nehmen die Gitterstörungen zu, so daß die 
mit 100 kN verpreßten Proben über eine größere Anzahl von Keimbildungsstellen 
im Vergleich mit den 20 und 50 kN verpreßten Proben verfügen, woraus dann die 
von uns beobachteten Umwandlungsgeschwindigkeiten in die bei Raumtemperatur 
stabile Modifikation III resultieren (s.Abb.3). 
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Abbildung 3 
Preßdruckinduzierte Phasenumwandlung für die mit 20 kN (2), 50 kN (3) und 100 
kN (1) komprimierte Carbamazepin-Modifikation II in die Form III in Abhängig-
keit von der 
Lagerungsdauer bei Raumtempera tur , durch DSC (offene Symbole) und mittels 
Röntgendiffraktometr ie (gefüllte Symbole) ermittelt. 
a= Umwandlungsgrad 
Lagerungszeit [d j 
Aus den genannten Gründen sind nach unserer Auffassung Aussagen über das 
Ausmaß von Modifikationsumwandlungen nur dann sinnvoll, wenn gleichzeitig der 
Untersuchungszeitpunkt eine Berücksichtigung findet. 
Aus der phänomenologischen Darstellung einer Phasenumwandlung, z.B. 
durch die Darstellung von zu unterschiedlichen Zeiten aufgenommener Röntgen-
diffraktogramme, kann der Umwandlungsgrad bestenfalls abgeschätzt werden. 
Aussagen zum zeitlichen Verlauf der Kinetik sind nur durch eine kontinuierliche 
Messung der Umwandlungsrate mit Hilfe geeigneter Methoden möglich. 
Sind nun die hier von mir angerissenen Probleme durch die Gundlagenfor-
schung gelöst und nach Rezepturoptimierung, die man heute mittels mathematischer 
Methoden (z.B. mit dem 23 Design) durchführt , wird die Arzneiform hergestellt 
und die in vitro-Liberation des Wirkstoffes aus der Arzneiform festgestellt. 
Mit der Prüfung der Lösungsgeschwindigkeit ist dann die Entwicklungsarbeit 
abgeschlossen, die Prüfung sollte in Zukunf t bei allen festen Arzneiformen in der 
Formulierungsphase als Routineprüfung nach einer offizinellen Methode durchge-
führt werden. Sie schließt sowohl die klinischen Versuchspräparate als auch die 
künftige Handelsform ein und stellt in immer stärkerem Maße die Grundlage für 
eine künftige in vitro/in vivo Korrelation dar. 
Die Kenntnisse von Zusammenhängen zwischen in vitro-Daten und entspre-
chenden in vivo-Befunden wird in Zukunft ein immer wesentlicheres Hilfsmittel für 
den Pharmazeutischen Technologen hinsichtlich der Rezepturoptimierung werden, 
da jede Entwicklungsarbeit immer stärker von einer bestimmten Zielrichtung der 
Arzneistoffliberation ausgeht. 
So kann es sinnvoll sein, einen Wirkstoff möglichst schnell in Lösung zu 
bringen, wie es für die große Zahl der Problemarzneistoffe gilt, um die Bioverfüg-
barkeit zu verbessern. 
Umgekehrt ist für Substanzen mit mehr oder weniger schneller Elimination 
anzustreben, die Freisetzung zu verzögern, um dadurch länger anhaltende Blutspie-
gel zu erzielen oder die Nebenwirkung von Wirkstoffen zurückzudrängen. 
In der Phase der Scaling up erfolgt schließlich die Überführung des Herstel-
lungsverfahrens einer Arzneiform vom Labormaßstab in den Produktionsmaßstab. 
Auf der Grundlage der gesammelten Erfahrungen während der durchlaufen-
den Präformulierung- und Formulierungsphase sollten die wichtigsten Eigenschaf-
ten des Endproduktes nicht oder nur wenig verändert werden, um die biologische 
Verfügbarkeit und damit die therapeutische Wirksamkeit des Präparates zu 
sichern. 
Daher ergeben sich insbesondere bei nicht homogenen Arzneiformen, dazu 
gehören auch die Tabletten, besondere Probleme bei der endgültigen Aufstellung 
der Fabrikationsvorschrift. 
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10. 
How Do Neurons Choose Partners for 
Communication? 
P R O F E S S O R J. R. WOLFF 
Developmental Neurobiology Unit, Dept. of Anatomy, 
Georg-August University Göttingen, FRG. 
In complicated interactive systems, and this includes the nervous system, 
choosing partners is one of the most difficult tasks. Since I do not speak your 
beautiful language I shall continue my lecture in the language which has most often 
served in partner-links between researchers over the last few decades. 
Bonyolult interaktív rendszerekben, így az idegrendszerben is, a partnerválasz-
tás a legnehezebb feladatok közé tartozik. Mivel nem beszélem az Önök szép 
nyelvét, előadásomat azon a nyelven folytatom, mely az utóbbi évtizedekben a 
kutatók közötti partnerkapcsolatokat leginkább szolgálta. — Let me therefore 
switch to English. 
In complex interactive systems, even more than selecting a suitable language, it 
is difficult to choose appropriate partners for communication. The following 
example may elucidate the type of difficulty which arises: A fruitful partnership has 
been established between the Albert Szent-Györgyi University and the University 
of Göttingen. We would probably run into serious problems, if we were asked to 
explain the success of this partnership merely by evaluating the overall structures 
and functions of the two institutions involved. On the other hand, it is obvious that 
much of this success is based on cooperation between individual scientists and 
laboratories. Thus, the functional significance of local interactions apparently 
increases, when they fit the needs of both the whole system and the interacting 
components. 
Similarly, neurobiological research has provided much evidence indicating 
that brain functions are closely related to interactions between specific sets of nerve 
cells. The functional development of the brain should then critically depend on how 
nerve cells choose partners for communication. This question includes three 
suppositions: nerve cells are capable of communication; nerve cells have specific 
communication partners; and nerve cells participate in the choice of their partners. 
I shall briefly discuss the validity of these assumptions, before we shall try to find an 
answer to the key question: Which criteria do nerve cells use for selecting 
communication partners? 
The first assumption, nerve cells are capable of communication, is based on 
characteristic properties of nerve cells or neurons. These may be summarized as 
follows: 
— Nerve cells release and receive signals 
— Signal transfer between neurons by "chemical transmitters" is directed 
through cell-to-cell contacts ("synapses") (Fig. 1). 
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— Nerve cells are polarized between transmitting and receiving modules 
which spatially separate the "pre- and post-synaptic elements" of each neuron. 
— Two types of post-synaptic effect ("excitation" and "inhibition") are 
mediated by separate neuron populations. 
— Synaptic messages regulate the probability of signal formation by disturbing 
the excitation-inhibition balance in the receiving neuron. 
P O L A R I Z A T I O N O F N E U R O N S A N D N E U R O N A L C O N T A C T S 
A: RECEPT IVE POLE 
"DENDRIT IC NODULE 
B: EMISSIVE POLE 
'AXON 1С NODULE' 
SYNAPSE' 
SYNAPTIC CONTACT BETWEEN 
NERVE CELLS " 1 " A " 2 " 
Fig. 1: Neurons are polarized cells. Presynaptic and postsynaptic elements spatially separate and 
accumulate (axons and dendrites, respectively). "Synapses" are contacts between pre- and postsynaptic 
elements which are specialized for directed signal transfer by chemical transmitters. Synaptic 
connections between neurons are restricted to the overlapping region between their "recept ive" and 
"emissive" poles. 
Thus, nerve cells indeed show cytological characteristics which make them 
suitable for intercellular communication. Apparently they form a cable-communi-
cation system with plug-and-socket-like contacts through which they may exert 
excitatory or inhibitory effects on each other. 
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The second question is, whether or not nerve cells have specific communication 
partners. There is an enormous complexity of intercellular connections in the 
nervous system and many of these connections may be neither stable nor specific. 
However, physiological, chemical and anatomical data suggest that neurons may 
have highly specific connections which characterize their function. We then have to 
ask: How specific are connections between neurons? 
— Between all neurons, connections are restricted by the range of their cell 
processes (Fig. 2). 
DENDRITIC MODULE AXONAL MODULE 
Fig. 2: Neurons can be classified according to the size, shape and position of their "dendritic" and/or 
"axonal modules". Projection neurons (A) have long axons and make synaptic contacts to target cells in 
remote positions (synapses of A and E). Local interneurons (B, C) have short axons and may focus their 
synapses on specific target cells, e.g. „basket cells" which effectively inhibit other neurons at their 
perikaryon (synapses of В on D). 
— Statistically, each neuron is connected to an extremely small subpopulation 
of all neurons (mammalian brains contain 107 to 10" neurons; each neuron forms 
and receives 10° to 104 synapses; the ratio between connected and unconnected 
neurons is therefore probably smaller than 1:1 million). 
— Neuron classes can be defined by the size and shape of their "receiving 
cables" and/or "transmitting cables" (see Figs. 1 and 2). 
— Projection neurons have long axons establishing synaptic contacts to 
specific target cells in remote positions (neuron A in Fig. 2). 
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— Local interneurons have short axons selectively innervating specific neigh-
bouring cells but avoiding others (e.g. "basket cells", neuron В in Fig. 2). 
— There are often countercurrent connections between neurons in different 
parts of the nervous system (see Fig. 3). 
C H A R A C T E R I S T I C N E T W O R K C O M P O N E N T S 
E X C I T A T O R Y C H A I N S 
FEED FOREWARD 
I N H I B I T I O N 
FEED BACK 
I N H I B I T I O N 
C O U N T E R C U R R E N T C O N N E C T I O N S 
FEED FOREWARD 
I N H I B I T I O N 
CV. .бег 
i 
MIXED TYPES OF 
I N H I B I T I O N 
О EXCTATORY NEURON INHIBITORY NEURON 
Fig. 3: Characteristic constellations of excitatory and inhibitory neurons which can be isolated from 
complex networks in the nervous systems. Note the characteristic involvement of various types of 
feed-forward- or feedback-inhibition. Dotted lines represent disregarded connections. 
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Thus, neuronal connections are selective, i.e. they are restricted to extremely 
small subpopulations of all neurons. Some of them are apparently specific, because 
they are focused on specific partner cells. 
The third suggestion is that neurons participate in the choice of their communi-
cation partners. This assumption is supported by experimental evidence. During 
ontogenesis, synaptic connections primarily show a relatively diffuse distribution 
but are secondarily specified. This remodelling is often based on selective 
elimination of synapses (Fig. 4.). On the other hand, selective sprouting of axons is 
observed when synaptic connections are lost (e.g. after lesions; Fig. 5). Reactive 
synaptogenesis reveals that a hierarchy exists in the specificity of neuronal 
connections. Thus, neurons are apparently involved in the choice of communication 
partners. The choice may be based on selective formation and/or elimination of 
synaptic connections. 
E L I M I N A T I O N O F S Y N A P S E S D U R I N G N O R M A L O N T O G E N E S I S 






DIFFUSE CONNECTIONS SPECIFIC ( 1 : ) CONNECTIONS 
Fig. 4: During ontogenesis, many connections between sets of neurons are secondarily specified by 
elimination of inappropriate connections. This may be based on a loss of axon collaterals, but may also 
include cell death of significant fractions of neurons. Thus, brain development shows critical periods of 
synaptic reorganization. These may result in „catastrophies" on the level of cells or networks and 
apparently serve to stabilize the surviving connections. 
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S Y N A P T I C R E O R G A N I Z A T I O N I N D U C E D B Y L E S I O N S 
, n o n - r e a c t i v e 
О • •-v о — о 
Fig. 5: In the adult nervous system, experimental lesions or pathological processes may induce synapse 
degeneration. This in turn results in synaptic reorganization, which may include selective sprouting of 
some axon types, while others do not react at all. Thus, re-innerveration is a selective process. Reactive 
synaptogenesis reveals a hierarchy of compensatory mechanisms which regulate the connectivity of the 
nervous system. 
Now, we may ask the main question: What are the conditions on which neurons 
form and stabilize connections to other neurons? We have seen that each synapse 
consists of pre- and postsynaptic elements. In certain conditions, however, one can 
observe supernumerous ("free" or "vacant") presynaptic or postsynaptic elements 
which did not find appropriate contact partners. This finding indicates that pre-and 
postsynaptic elements may be formed or eliminated independently from each 
other. Therefore, the stabilization of a synapse seems to depend on proper 
conditions in both the presynaptic neuron and the postsynaptic neuron. We then 
have to specify our question by asking: What are the conditions in which neurons 
form and maintain presynaptic or postsynaptic elements? And are these conditions 
different for excitatory and inhibitory synapses? 
In vivo and vitro experiments suggest that increased excitation of neurons 
stimulates the formation of presynaptic elements. In addition, there is indirect 
evidence that loss of inhibition may have a similar effect as increased excitation. On 
the other hand, increased inhibition and a loss of excitation may reduce the growth 
of axons and. therefore, reduce the number of presynaptic elements. At present , 
there is no evidence that excitatory and inhibitory neurons react in a different 
manner (Fig. 6). 
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RESPONDING SYNAPSE COMPONENT CHANGES 
E f I f 
IN INPUT 
E f I f 
presynaptic elements 
I 
+ ( + ) 
+ ( + ) 
— — 
postsynaptic elements ^ - ( - ) 
(+) (+) 
+ + 
E/I T E/I 1 
On the other hand, are there conditions that promote the formation of 
postsynaptic elements? We know very little about the dynamics of postsynaptic 
elements of inhibitory synapses. These synapses tend to accumulate on perikarya 
and on proximal dendrites rather than on peripheral ones. This distribution pattern 
indicates that inhibitory postsynaptic elements increase in number where excitatory 
postsynaptic potentials converge and summate. On the other hand, there are 
reports on hypersensitivity for inhibitory transmitters developing as a consequence 
of decresased or lost inhibitory input. These have been tentatively summarized as 
shown in the last row of Fig. 6. 
1 1 I I I I I I I I 
20 60 100 1kQ 200 T[°C) 
Fig. 6: Schcmc of synaptic plasticity reactions following longterm disturbances of the excitation/inhibi-
tion balance (E/l) . These reactions may be induced by changes in input (E f , I ; I f , i ) but also by 
other factors such as certain hormones, growth promoting factors, etc. (not included). "Plus": increase 
in number or efficacy of pre- or postsynaptic elements, i. e. their formation is promoted and/or their 
breakdown is diminished. "Minus": decrease in number or efficacy of synaptic elements, formation 
retarded and/or breakdown increased. Brackets indicate that direct experimental evidence is not yet 
available, but circumstantial evidence exists (for details see Wolff und Wagner, 1983: Dammasch et al. 
1986: Wagner and Wolff. 1988). 
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Vacant postsynapic densities of excitatory synapses transiently occur in various 
parts of the nervous system. Experimentally, their appearance can be induced by 
lesions which destroy excitatory axon systems. Thus, when the excitatory input 
decreases vacant postsynaptic elements for making excitatory synapses appear (Fig. 
6). Since inhibition can decrease the efficacy of excitatory input in postsynaptic 
neurons, one may wonder whether increased inhibition affects the number of 
"vacant" (excitatory) postsynaptic elements in a similar manner as reduced 
excitation. 
At this point, I shall briefly summarize some results which were obtained in a 
long lasting cooperation with colleagues from Szeged (listed below). 












Biological Research Center 
(Molecular Neurobiology Unit) 
Szent-Györgyi Albert Medical University 
(Central Research Laboratory) 
Attila József University 
(Dept. of Comparative Physiology) 
Co-workers in Göttingen 




LEUTGEB, U. Georg August University 
MICHLER, A. (Dept. of Anatomy and Neurology) 
RICKMANN, M. 
WAGNER, G. 
For most of these multidisciplinary studies, we selected the superior cervical 
ganglion. In rats, this ganglion contains a relatively small set of neurons which 
receive excitatory input via acetylcholinergic axons from the spinal cord. The 
principal ganglion cells provide the sympathetic (noradrenergic) innervation to the 
head region. It was demonstrated that, apart from other interneurons, this ganglion 
includes GABAergic components. These are driven by preganglionic input and 
inhibit the principal ganglion cells (Fig. 7 A, Wolff et al., 186; Kása et al., 1988). The 
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SYMPATHETIC I НИ CEE ATI ОН 
OP TIE HEAD EEC10H 
Fig. 7; Scheme of synaptic components and neuroplastic reactions in the superior cervical ganglion of rats. A: normal ganglion (S1F cells and other 
interneurons are not shown); B: foreign nerve implanted into the normal ganglion is not able to make functional synapses; C: after partial de-afferentation 
(interruption of preganglionic axons) implanted acetylcholinergic nerves do make functional synapses on principal ganglion cells; D: a surplus of inhibition 
induced by exogenous G A B A provides conditions in which implanted nerves do make synapses in the presence of intact preganglionic nerves. 
existence of an endogenous GABA-system may explain why externally applied 
GABA (gamma- aminobutyric acid) strongly inhibits the activation of ganglion 
cells when the preganglionic nerve trunk is stimulated (Farkas et al., 1986). 
The superior cervical ganglion was a suitable model for our experiments, 
(review see Wolff et al., 1987) because it had been previously demonstrated that the 
hypoglossal or vagal nerve can be implanted in vivo into this ganglion. We 
confirmed that the foreign nerve does not make synapses in this ganglion as long as 
the preganglionic nerve is intact (Fig. 7B). We also confirmed that the implanted 
nerve does, however, make functional (acetylcholinergic) synapses on ganglion 
cells when the preganglionic nerve had previously been cut, at least partially (Fig. 
7C). Interestingly enough, long-term application of exogenous GABA induced the 
formation of vacant postsynaptic densities for excitatory synapses. In addition, the 
number of acetylcholin-receptors transiently increased ("hypersensitivity), if 
GABA was infused into ganglia with an intact preganglionic nerve. In other words, 
if none of the above-mentioned nerves was implanted in addition to the GABA-
applicator, the nerve was able to make functional synapses on ganglion cells, 
although the preganglionic nerve was intact (Fig. 7D). This indicates that both 
decrease of excitatory input and hyperinhibition have a similar effect on the 
acceptance of excitatory synapses (Fig. 6). 
In both cases, the formation of synapses depends on additional (acetylcholiner-
gic) presynaptic elements provided by the implanted (regenerating) nerve. Viewed 
from the level of the organism, the „double innervation" of a sympathetic ganglion 
by a preganglionic sympathetic nerve and a motor nerve (hypoglossal n.) or a 
parasympathetic nerve (vagal n.) does not make sense. At the cellular level, 
however, ganglion cells may overcome hyperinhibtion by additional excitatory 
input. This indicates that the amount of pre- and/or postsynaptic elements formed 
and stabilized by neurons depends on local conditions. If these conditions change, 
neurons will show plastic reactions and the synaptic connections will be reorganized, 
if appropriate partners can be found. 
This "trophic" effect of hyperinhibition is not specific for GABA. Similar 
plastic responses may be induced by long-term application of sodium bromide 
(NaBr, „tranquillizer of the 19th century") which does not require local application, 
but is taken orally via the drinking water in therapeutic-like doses (140—280 jig/1). 
Thus, synaptic plasticity can also be induced by long-term pharmacotherapy of 
drugs which increase neural inhibition. 
In normal conditions, inhibition and excitation of neurons mainly depends on 
synaptic input (and in some cases on hormonal effects). Synaptic input is regulated 
by transneuronal interactions. In Fig. 8A-C it is demonstrated how such transsynap-
tic effects might influence the formation and stabilization of synapses. Probably, 
such mechanisms are also involved in normal synapse formation, because characte-
ristic combinations of excitatory and inhibitory neurons are found in the brain and 
spinal cord (Fig. 3). 
We may summarize this view of how neurons choose communication partners, 
as follows: 
— The choice of communication partners is based on selective stabilization 
and breakdown of synapses. 
— In each neuron, the balance between excitation and inhibition plays a role in 
the stabilization or elimination of synapses. 
— A neuron may distinguish between "good" and "bad" synapses depending 
on whether they stabilize or disturb the balance. 
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; 
Fig. 8: Cartoon-like illustration of how neurons may cooperate in the formation and stabilizion of 
synaptic connections within small networks. 
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— In this way, each neuron may choose communication partners because of 
their local effects. 
— Since synaptic effects depend on cell-to-cell interactions in neuronal 
networks, synapse formation can compensate disbalanced states of neuronal 
networks, and vice versa. 
— In this way, synaptic connections may be adapted to the requirements of the 
nervous system and may be modified by sensory input, although their formation 
and maintenance is based on local decisions. 
— We may conclude that the choice of communication partners in the nervous 
system is itself a result of communication between neurons and neuronal networks. 
Implications and applications of this concept 
It is proposed that synaptic connections are formed, maintained or eliminated 
according to rules which tend to compensate disturbances of the excitation-inhibi-
tion balance of the neurons concerned (see Fig. 6). The rules are based on extreme 
simplifications and their experimental basis is still imcomplete. The heuristic value 
of such a working hypothesis obviously depends on whether or not it leads to new 
approaches to the nervous system. Here, I shall focus on four aspects of 
neurobiology: 
Basic research: It is difficult to study interaction mechanisms in complex 
systems. One of the major obstacles is that experiments require identical reproduc-
tion which can hardly be achieved in complex interactive systems. One way to 
overcome this restriction is the formalization of theories followed by computer 
simulation. Biological experiments may then be restricted to testing critical 
predictions from "simulated experiments". This can be done with the "compensa-
tion theory of synaptogenesis" (see Wolff and Wagner, 1983; Dammasch et al., 
1986). 
Ontogenesis: It is one of the challenges of developmental neurobiology to 
explain the interaction between genetic information and epigenetic mechanisms. 
The concept predicts that brain development is regulated by at least three types of 
factors: (1) Trophic factors comprise all agents and conditions (including synaptic 
input) which affect any part of the molecular cascade which leads to formation or 
breakdown of pre- or postsynaptic elements and/or synaptic contacts; (2) spatial 
and temporal maturation patterns of excititatory and inhibitory neurons; (3) 
environmental factors include not only information transfer from sensory organs 
and noxious influences on the formation or stabilization of synapses. 
Pathology: The concept claims that the stability of connections in the normal 
brain results from a dynamic equilibrium of productive and degrading mechanisms. 
Following lesions, we will have to identify different conditions in which synaptic 
reorganization either results in functional rehabilitation or leads to progressive 
dysfunction (degenerative diseases). 
Pharmaco-therapy: According to the compensation theory of synaptogenesis, 
we have to be aware of the possibility that synaptic connections may be modified by 
long-term application of drugs which interfere with synaptic transmission. 
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